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ABSTRACT: A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component,
NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the
HTS based on the known phenothiazine Ndh inhibitors, triﬂuoperazine and thioridazine. Combined HTS (11000 compounds)
and in-house screening of a limited number of quinolones (50 compounds) identiﬁed ∼100 hits and four distinct chemotypes,
the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone
library (350 compounds) identiﬁed a further ∼90 hits across three quinolone subtemplates. Quinolones containing the amine-
based side chain were selected as the pharmacophore for further modiﬁcation, resulting in metabolically stable quinolones
eﬀective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis
activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable
pharmacokinetic and toxicological proﬁles.
■ INTRODUCTION
In 2014, tuberculosis (TB) globally infected 9.6 million people,
resulting in an estimated 1.5 million deaths.1With the emergence
of multidrug resistant (MDR) and extensively drug resistant
(XDR) TB, the need for new drug treatments targeting the
disease has never been greater.2 Current ﬁrst line drugs for
TB were developed in 1952−1966 (Figure 1). Shortcomings of
these drugs include: (i) long treatment regimens (6−9 months),
leading to patient noncompliance, (ii) adverse drug−drug
interactions with anti HIV drugs (HIV/AIDS is a common
coinfection), and (iii) limited or no activity against MDR and
XDR Mycobacterium tuberculosis (Mtb).3 Bedaquiline4,5 and
delamanid6,7 are the only recently FDA approved drugs for the
treatment of TB, and their approval is currently only for MDR in
cases where established treatments have failed (Figure 1).8
To ﬁnd an eﬀective treatment for MDR and XDR, it is believed
that a drug with a novel mode of action is required in order to
circumvent resistance.
Targeting components of theMtb respiratory chain (Figure 2)
has been shown by us and other laboratories to be eﬀective in
sterilizing both replicating and dormant Mtb.9−18 The initial
target within this program, Ndh (Rv1854c), is a single subunit
50 kDa enzyme involved in the redox reaction of NADH
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oxidation with subsequent menaquinol production. Ndh has
been biochemically identiﬁed as a “choke point” and as such is
essential for cell function and viability.19 Essentiality of ndh
has been shown by the inability of Mtb to tolerate insertion
mutations in this gene20 and more recently in a study involving
ndh knockout with subsequent conﬁrmation by complementa-
tion.21 The other NADH-dependent electron donating dehy-
drogenases identiﬁed in the genome (complex I and ndhA) have
been shown not to be lethal.18,22 These data are consistent with
biochemical evidence that Ndh is a major source of electrons for
the ETC.
Respiratory-chain inhibition-induced death represents a funda-
mental shift from traditional antitubercular drug design that have
until recently relied on drugs that selectively target the replication
machinery of Mtb.9,23−28 Antitubercular drugs developed to
target the respiratory pathways should therefore have the
potential to have sterilizing activity against current MDR and
XDR Mtb strains.
Identiﬁcation of hit compounds was achieved through a HTS
screen of approximately 11000 compounds that were predicted
to possess activity against the Ndh enzyme. Ndh was chosen for
the HTS due to the critical role as an important dehydrogenase
during growth and pathogenicity9,17 and due to its tractability
for heterologous expression in Escherichia coli and HTS.29
The enzyme has been observed to be sensitive to phenothiazine-
based inhibitors such as triﬂuoperazine and thioridazine.9 These
inhibitors have been shown by a number of diﬀerent laboratories
to have sterilizing activity against replicating and slow growing
Figure 1. Current ﬁrst line drugs used to treat tuberculosis and recently approved drugs for the treatment of MDR TB.
Figure 2. Schematic representation of the respiratory chain ofM. tuberculosis. The chain components are: Ndh/NdhA, type II NADH:(mena)quinone
oxidoreductase (two isoforms); ETF, electron transferring ﬂavoprotein (transfer of reducing equivalents from fatty acid β-oxidation into the Q-pool);
nuo, protonmotive NADH dehydrogenase (complex I), bcc, cytochrome−bcc complex (note that there is no evidence for soluble cytochrome c in this
organism); aa3, cytochrome bcc oxidase, postulated to form a supercomplex with bcc. An alternative terminal oxidase pathway is utilized inM. tuberculosis
under conditions of low oxygen tension containing quinol oxidase (cytochrome bd), fumarate reductase (FRD), and nitrate reductase (nar)
components. P and n correspond to the positive and negative sides of the respiratorymembrane with respect to proton translocation. Protonmovements
are indicative only and do not represent H+/e− ratios for the respective complexes.
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MDR Mtb (grown anaerobically) in both in vitro and in vivo
models.14,30,31 These two compounds were used as the basis to
employ a range of ligand-based chemoinformatics methods32−35
in the rational selection of the ∼11000 compounds for the
HTS campaign (selected from a commercial library of ∼750000
compounds (Biofocus DPI)).36−40 Selected compounds were
subject to a sequential high throughput screening campaign
using an in vitro assay against recombinant Ndh as described
previously.29
In addition to the HTS screen, a limited selection of 50 quino-
lones were also screened in-house against Mtb Ndh. These
compounds were selected for their structural diversity from a
library of quinolones designed to target the NADH:ubiquinone
oxidoreductase within the malaria parasite Plasmodium falcipa-
rum (PfNDH2) as described previously.41−44 The HTS screen
and in-house screen in combination generated ∼100 hits across
four distinct templates, the most potent of which were also tested
for whole cell replicating Mtb activity. Following analysis of the
in vitro biological data, predicted DMPK properties and
investigations into chemical tractability the quinolone template
was selected as the most promising for further development.
In previous antimalarial discovery projects,41−48 the inhibitors
based on the quinolone core displayed pharmacodynamics
consistent of a privileged pharmacophore, with the ability to
act on multiple electron transport chain (ETC) components.
For example, quinolones with a dual mechanism of action against
two respiratory enzymes, PfNDH2 and cytochrome bc1, have
recently been reported.43 To exploit this phenomenon in this
antitubercular discovery project, further screening and SAR
investigations was switched to whole cell replicating TB activity.
To fully establish the structure−activity relationship (SAR)
within the existing quinolone library with respect to whole cell
Mtb activity, a further library of∼350 compounds were screened
against replicating Mtb. There were ∼90 compounds that
were found to inhibit Mtb growth by >50% at 5 μM. Four
subtemplates were then identiﬁed as having moderate in vitro
Mtb potency. The most promising of which only had a very
limited number of examples (seeTable S1, Supporting Information)
within the existing library but demonstrated signiﬁcantly more
potency, as such, the template based on compounds 1 and 2 was
chosen for lead optimization (Figure 3).
A comprehensive medicinal chemistry SAR study around this
series was then undertaken to establish optimized leads for
further development. Screening data analysis (see Table S1,
Supporting Information) shows NH2 and OAc at the 4-position
are inactive for this particular subtemplate (Table S1, entries 20,
23, and 24, Supporting Information) and show reduced activity
for other quinolone subtemplates. Replacement of the phenyl
ring with a pyridyl ring also rendered the subtemplate inactive
(Table S1, entry 20, Supporting Information). Modiﬁcation of
ring C results in a loss of in vitro Mtb potency and is a general
trend that was seen across most quinolone subtemplates screened.
Modiﬁcations of particular interest were therefore optimization of
the side chain to optimize potency and DMPK, the nature
of the group at 3-position and the electronic/steric eﬀect of
substituents placed at the 5, 6, and 7 positions (Figure 4).
■ CHEMISTRY
Following identiﬁcation of quinolones 1 and 2 as the initial hits
against Mtb, our initial eﬀorts were focused on exploring the
SAR of substituents placed in the A ring. The synthesis of these
compounds was achieved in 3−5 steps from commercially
available starting materials (Scheme 1). Oxazoline 4 was
prepared from the corresponding isatoic anhydride 3 in
yields of 34−75%. Where the isatoic anhydride was not commer-
cially available, the oxazolines were synthesized in-house
(see Supporting Information). 4′-Fluoropropiophenone 5 was
allowed to react with piperidine to give ketone 6 in 32−97% yields.
Figure 3. Identiﬁcation of the quinolone template for lead optimization.
Figure 4. Known SAR and SAR to be investigated.
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Reaction of oxazoline 4 with ketone 6 in the presence of triﬂic
acid gave the desired quinolones 1, 2, and 7a−k in 23−45%
yields (Table 1).
The nature of the group at 3-position of the quinolone was also
studied. A small set of analogues with a hydrogen at 3-position
were synthesized (Scheme 2). Substituted 2-aminoacetophe-
none 9 was converted from the respective aminobenzoic acid 8
using methyl lithium in 36% yield. 4-Fluorobenzoate 10 was
reacted with piperidine in the presence of potassium carbonate to
give the piperidinyl benzoate 11 in 37% yield. Benzoate 11 was
hydrolyzed to benzoic acid, which was then converted to acid
chloride 12 by oxalyl chloride. Acylation of 2-aminoacetophe-
none 9 with acid chloride 12 provided the intermediate 13
in 30−51% yields. Cyclization of the intermediate 13 in the
presence of NaOH or KOtBu gave the 3-H quinolones 14a−c in
41−91% yields (Table 2).
Literature precedent from the development of ETC inhibitors
in the antimalarial ﬁeld lead us then to look at the presence
of a halide at the 3-position. GSK’s pyridone series49 demon-
strated tolerance of the presence of a chlorine at 3-position,
and within our own group we have shown the combination of
3-chloro-7-methoxy enhances biological activity of the quinolone
core.50 To achieve this, the 3-H compounds were treated with
sodium dichloroisocyanurate and sodium hydroxide to give
3-Cl quinolones 15a−d in 40−61% yields or NBS to give 3-Br
quinolones 15e−f in 55−63% yields.
Having identiﬁed 3-methyl and 5,7-diﬂuoro quinolone
(followed by 6-ﬂuoro-7-methoxy and 7-methoxy quinolone) to
be optimal for Mtb activity (see Table 8), the focus of SAR
explorationsmoved to the terminal ring of the side chain to further
improve Mtb activity and optimize DMPK. Additional small
groups, such as Me, F, and CF3, attached at diﬀerent positions on
the terminal piperidine ring were investigated. In addition, the
eﬀect of chirality was explored.51 Synthesis of compounds 17a−k
was achieved using chemistry described in Scheme 3 (Table 3).
Incorporation of diﬀerent amino groups into the side chain as
an alternative to the potentially metabolically labile piperidine
ring was also investigated. To incorporate a diethylamine group,
an alternative methodology was used to synthesize the side chain,
commercially available 4-bromo-N,N-dimethylaniline 18 was
treated with butyllithium for a lithium−halogen exchange and
the intermediate was quenched withN,N-dimethylpropionamide
to form the side chain 19 in 78% yield, reaction with oxazoline 4h
was then carried out to give quinolone 17l in 46% yield (Scheme 4).
Extension of the side chain with a phenyl or benzyl group at
the 2-position was also investigated using the synthetic metho-
dologies shown in Scheme 5 (Table 4). In addition, replacement
of piperidine by piperazine was investigated. This was to further
explore the length of side chain that could be tolerated and to
improve the solubility.
In addition, the quinolone with a piperidine ring at the meta-
position 24 was also synthesized by reacting the 3-bromopro-
piophenone 22 with piperidine using Buchwald coupling to yield
the ketone intermediate 23, which was coupled with oxazoline 4h
to give the quinolone in 45% yield (Scheme 6).
A series of analogues with a pyrrole heterocycle in the side
chain were also synthesized to further explore the side chain SAR
and enhance the metabolic stability. The synthetic route to these
compounds is illustrated in Scheme 7. Utilizing copper and trans-
N,N′-dimethyl-1,2-cyclohexanediamine catalyzed N-arylation
with 4-bromopropiophenone, the side chain ketone intermediate
31 was formed in 30−62% yields.52,53 Final cyclization with
oxazoline gave quinolones 32a−g in 35−57% yields (Table 5).
Using ﬂuorine to block metabolism and improve oral absorp-
tions was further explored. Research by Smith has shown that
gem-diﬂuorinated piperidine compounds exhibited a signiﬁcant
Scheme 1. Synthesis of Quinolones 1, 2, and 7a−ka
aConditions and reagents: (a) 2-amino-2-methyl-propanol, ZnCl2, PhCl, 135 °C, 24 h; (b) corresponding amine, K2CO3, DMF, 120 °C to reﬂux,
overnight; (c) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
Table 1. Yields for the Synthesis of Compounds 1, 2, 7a−k
compd X R % yield 4 % yield 6 % yield 7
1 H H 62 23
2 7-OMe H 75 62 36
7a 6-F H 60 62 26
7b 6-OMe, 7-OMe H 52 62 28
7c 6-Cl, 7-OMe H 45 62 35
7d 6-F, 7-OMe H 52 62 41
7e 5-OMe, 7-OMe H 58 62 32
7f 5-F,7-F H 68 62 45
7g 7-F H 62 35
7h 7-Cl H 64 62 37
7i H F 55 36
7j 7-OMe F 75 55 43
7k 5-F, 7-F F 68 55 29
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improvement in metabolic stability.54 This led to the design and
synthesis of ﬂuorinated quinolones 38a−f as well as the alcohol
side chain quinolones 38g−i. The chemistry used in the synthesis
of these compounds is shown in Scheme 8 (Table 6).
Removal of the benzyl group from the chiral proline derivatives
38j−lwas achieved using hydrogenation (Scheme 9) in good yields.
For the gem-diﬂuoro analogues (42a (MTC420) and 42b),
4-bromopropiophenone was ﬁrst converted to a more reac-
tive 4-iodopropiophenone by an aromatic Finkelstein reaction
catalyzed by copper(I) iodide in combination with N,N-dimethyl-
1,2-diaminoethane.55 A subsequent Buchwald−Hartwig amina-
tion using Pd2(dba)3 and Xantphos with the gem-ﬂuorinated
amine gave the ketone side chain 41a−b in 12−28% yields.56
Reaction with oxazoline gave quinolones 42a−b in 47−56% yields
(Scheme 10).
42a was identiﬁed as the lead compound in the series as it
exhibited good potency and metabolic stability (See Table 11
and Table 12), and further investigation of the pyrrolidine side
Scheme 2. Synthesis of Quinolones 14a−c and 15a−fa
aConditions and reagents: (a) MeLi, DME, 0 °C, 2 h; (b) (i) K2CO3, DMF, reﬂux, overnight, (ii) NaOH (aq), MeOH, reﬂux, overnight; (c) oxalyl
chloride, DCM, DMF (cat.), rt, 2 h; (d) NEt3, THF, rt, overnight; (e) NaOH (s), 1,4-dioxane, 110 °C, 5 h or KO
tBu, tBuOH, 75 °C, 16 h;
(f) sodium dichloroisocyanurate, 1 M NaOH (aq), MeOH, rt, overnight (15a−d) or NBS, DCM, DMF, rt, overnight (15e−f).
Table 2. Yields for the Synthesis of Compounds 14a−c and 15a−f
compd X R Y % yield 9 % yield 11 % yield 13 % yield 14 % yield 15
14a H H H 51 70
14b OMe H H 36 50 41
14c OMe F H 36 37 30 68
15a H H Cl 51 70 40
15b OMe H Cl 36 50 41 61
15c OMe F Cl 36 37 30 68 52
15d H F Cl 37 60 91 58
15e H H Br 51 70 63
15f H F Br 37 60 91 55
Scheme 3. Synthesis of Quinolones 17a−ka
aConditions and reagents: (a) corresponding amine, K2CO3, DMF, 120 °C to reﬂux, overnight; (b) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
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chain was undertaken to improve solubility and potency. Further
modiﬁcations have included adding chirality and introducing
amide functionality to rapidly ascertain if it is tolerated within
the template. Quinolones 45a−h were therefore synthesized
using chemistry described in Scheme 11. To incorporate the
amide group, Ullmann coupling of 4-bromopropiophenone with
D-proline gave the carboxylic acid intermediate 43a−b. Cross-
linking the carboxylic acid by EDC/NHS to the respective amine
provided the ketone side chain 44 in 52−90% yields. This was
subsequently coupled with oxazoline in 12−34% yields to aﬀord
quinolones 45a−g.
Incorporation of an amide moiety largely resulted in reduced
antituberculosis activity (Table 7). As such, our attention
returned to 42a and improving its pharmacokinetic proﬁle.
Use of a pro-drug strategy, previously used successfully within
other quinolone development programs57 was investigated,
leading to the synthesis of compound 46 (Scheme 12).
Compound 46 was synthesized by reacting 42a with potassium
tert-butoxide and acetyl chloride to give the acetate pro-drug in
high yield.
■ RESULTS AND DISCUSSION
Structure−Activity Relationships (SAR). Initial SAR
investigations around the hit compounds 1 and 2 focused on
establishing the optimal A-ring substituents (X). Compounds 1,
2, and 7a−7h demonstrate the most favorable X groups are 5-F,
7-F, closely followed by 6-F, 7-OMe, and 7-OMe. Compounds
7i−7k were synthesized with a view to reducing the potential
metabolism of the piperidine ring. Pleasingly, a good level of
potency was maintained. Concomitantly, the potential for
replacing the methyl group at Y was also investigated. When
Y = H, activity is lost, as demonstrated by compounds 14a−c.
Halogenation was also investigated; again this largely resulted in
reduced antituberculosis activity (15a−f), the one exception to
this being 15e possessing a Br at Y. This aﬀect appeared to be
compound speciﬁc rather than a general trend across all
brominated analogues, and as such it was decided that the
methyl group was the optimal group at this position (Table 8).
With 5-F, 7-F and 3-methyl conﬁrmed as optimal for
antituberculosis activity, optimizing the side chain then became
the focus of the SAR studies (Table 9). Initial investigations
into piperidine ring substituents at the 4-position revealed that
in addition to 4-F 7k, a methyl group is also tolerated as
demonstrated with compound 17b. It rapidly became apparent
that there was a size limitation to the group tolerated at the
4-position with larger groups such as CF3, cyclopropyl, and gem-
diﬂuoro, resulting in loss of potency. Movement of the F and
Me groups to the 3-position resulted in improvements in anti-
tuberculosis activity as demonstrated by compounds 17e−h.
Interestingly, racemic and enatiomerically pure analogues of the
3-methyl derivative 17f showed little variation in potency, which
is in direct contrast to the pyrrolidine analogues discussed later.
Replacement of the piperidine ring with a number of alternative
amines was also investigated. Increasing ring size (17j) and use of
dimethyl amine (17l) retained good potency. Incorporation
of secondary amines (17k) and more polar groups such as
N-methyl piperazine (17i) reduced antituberculosis activity.
Moving the piperidine group from the para to the meta-position
(24) also resulted in loss of activity.
The size limitation and unfavorable incorporation of piperazine
was further conﬁrmed by our concomitant investigation into
extended side chain analogues (Table 10). The aim of this series
was to explore the space available and to improve solubility with
the incorporation of piperazine to facilitate salt-based formulation.
Table 3. Yields for the Synthesis of Compounds 17a−k
Scheme 4. Synthesis of Quinolone 17la
aConditions and reagents: (a) (i) nBuLi, Et2O, −78 °C, 30 min, (ii) N,N-dimethylpropionamide, −78 °C to rt, 2 h; (b) CF3SO3H, n-BuOH, N2, 130
°C, 24 h.
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With this information in hand, several small heterocyclic,
ﬂuorinated, chiral, and amide analogues were synthesized to
investigate SAR and improve DMPK (Table 11). Compounds
32a−g are pyrrole derivatives. An unsubstituted pyrrole moiety is
well tolerated in the 5-F (32d) and 5-F, 7-F (32e) analogues,
however, increasing the size of the pyrrole group by addition
of a fused benzene ring (32b) again results in loss of potency.
Incorporation of a halogen on the aromatic ring was also
investigated but reduced potency.
Fluorinated analogues were synthesized in order to improve
metabolic stability (see Table 11). Both mono (38a and 38b)
and gem-diﬂuoro (42a) substituted pyrrolidine derivatives
exhibited good to excellent potency. The gem-diﬂuoro azetidine
(38c) and 3-substituted piperidine (42b) also demonstrated
good potency. Incorporation of an alcohol group in the side
chain to reduce lipophilicity and potentially facilitate pro-drug
approaches provided mixed results. gem-Methyl, OH analogues
38g−iwere not tolerated, whereas inclusion of prolinol (39a−b)
gave good antituberculosis activity. Benzylated analogue 38j and
amide analogues 45a−g largely resulted in loss of potency. For
the pyrrolidine analogues, the eﬀect of chirality on activity was
markedwith the (R)-3-ﬂuoro analogue 38a (Mtb IC50 = 0.23μM),
demonstrating signiﬁcantly superior potency over the (S)-3-
ﬂuoro analogue 38b (Mtb IC50 = 1.80 μM). The eﬀect of chirality
was also observed with the prolinol analogues, (S)-prolinol
analogue 39b (Mtb IC50 = 0.32 μM) being more active than
(R)-prolinol analogue 39a (Mtb IC50 = 1.52 μM). The overall
SAR trends for the series can be seen in Figure 5.
In Vitro DMPK and Toxicity. Analogues demonstrating
good potency were then moved through our screening cascade
and evaluated for microsomal turnover and HEPG2 cytotoxicity.
None of the compounds were found to be cytotoxic, and all had
good therapeutic indexes. From the earlier analogues tested
(entries 1−6 in Table 12), it was apparent that the compounds
were being metabolized quickly by liver microsomes. Resolving
this issue was therefore the driving force for a large proportion of
the medicinal chemistry manipulations described in Table 11
above.
Two strategies were employed to address the metabolic
stability issues (Figure 6). The ﬁrst was to replace the piperidine
ring with an alternative heterocycle. Among those selected,
pyrrole (32e) provided the most active compound with a modest
improvement in metabolic stability. Fluorination of the pyrrole
(38d) at the 3 and 4 positions resulted in complete resolution
of metabolic instability; however, antituberculosis activity was
also lost. From earlier SAR studies, we knew that replacing the
piperidine ring (7f) with a pyrrolidine ring (17l) was tolerated in
terms of activity and may provide us with more opportunity
to modify the ring in what we believe to be a limited space.
Monoﬂuorination (38a) provided a verymodest improvement in
stability. Subsequent synthesis of the gem-diﬂuoro analogue
(42a), however, provided us with a compound with both good
antituberculosis activity and excellent metabolic stability. The
equivalent six-membered ring analogue 42b had good potency
but comparatively decreased metabolic stability as expected
(Table 12).
Selected analogues were also measured for Caco-2 perme-
ability, stability in plasma, % plasma protein binding (PPB), and
solubility (Table 13). All compounds performed well in these
assays with the exception of solubility, which is a common issue
for the quinolone chemotype.
Scheme 5. Synthesis of Quinolones 21a−ga
aConditions and reagents: (a) corresponding amine, K2CO3, DMF, 120 °C to reﬂux, overnight; (b) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
Table 4. Yields for the Synthesis of Compounds 21a−g
compd X A B % yield 20 % yield 21
21a H CH CH2Ph 64 33
21b 6-F CH CH2Ph 64 40
21c 7-OMe CH CH2Ph 64 42
21d H N CH2Ph 58 30
21e 6-F N CH2Ph 58 28
21f 7-OMe N Ph 64 30
21g 7-OMe N CH2Ph 58 38
Scheme 6. Synthesis of Quinolone 24a
aConditions and reagents: (a) piperidine, Pd(OAc)2, XPhos, NaO
tBu, toluene, 110 °C, 24 h; (b) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
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A number of analogues also underwent additional in vitro
DMPK(Table 14) experiments, further conﬁrming themetabolism
issues detailed above.
Biological Proﬁle.Having selected 42a as the lead compound,
full biological proﬁling was undertaken to establish its pharmaco-
kinetic and toxicological proﬁle in addition to its activity against
slow-growing (Wayne assay) and MDR-resistant Mtb (Table 15).
42a demonstrated comparable activity against all tested strains
of sensitive andMDRMtb as well as having good potency against
dormant, nonreplicating TB. It demonstrated a suitable in vitro
DMPK and toxicity proﬁle to undergo in vivo pharmacokinetic
analysis.
Pharmacokinetics. The pharmacokinetic proﬁle of 42a can
be seen in Figure 7 and Table 16. Analysis of data from the parent
Scheme 7. Synthesis of Quinolones 32a−ga
aConditions and reagents: (a) EtMgBr, THF, 0 °C, 1 h; (b) PCC, DCM, rt, 2 h; (c) 5 mol % CuI, 20 mol % trans-N,N′-dimethyl-
1,2cyclohexanediamine, K3PO4, toluene, 110 °C, 24 h; (d) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
Table 5. Yields for the Synthesis of Compounds 32a−g
Scheme 8. Synthesis of Quinolones 38a−la
aConditions and reagents: (a) corresponding amine, K2CO3, DMF, 120 °C to reﬂux, overnight; (b) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
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compound indicated solubility limited absorption as the PK did
not increase linearly with dose from 10 to 50 mg/kg. At this
point, the acetate pro-drug strategy was deployed in an attempt
to improve exposure.
Initial ﬁndings with both the 10 and 50 mg/kg dose of pro-
drug demonstrated a signiﬁcant increase in overall exposure as
indicated by a signiﬁcantly increased AUC, Cmax accompanied by
increased bioavailability.
Metabolite ID work was undertaken to establish the metabolic
activity exerted upon 46 (Figure 8 and Table 17).
In the study, ﬁve metabolites were detected in the urine and
bile of SD rats dosed with 46. These metabolites were named as
M1 through to M5 based on their eluting time under HPLC
conditions. Among the ﬁve metabolites, M1, M2, and M3 were
identiﬁed as dihydroxy 42a, M4 was identiﬁed as hydroxylated
42a, and M5 was identiﬁed as active drug 42a. Location of the
hydroxyl groups was established through mass spectrometry
fragmentation patterns (see Supporting Information). M3 to M5
were detected both in urine and bile samples, and M1 and M2
were only detected in the bile sample.
The presence of the pro-drug in the rat urine indicates that
the pro-drug does not completely break down to its active
metabolites as predicted. As the plasma levels obtained are a
measure of parent drug only, they are not a true representation
of the drug levels present. Studies are currently underway to
establish if a more suitable pro-drug can be synthesized that will
resolve the issue and provide a compound suitable for in vivo
eﬃcacy testing.
■ CONCLUSIONS
To conclude, a 3−6 step synthesis of a range of 2-mono aryl
amine 3-methyl quinolones with potent antituberculosis activity
has been reported. Compounds have been developed that
are metabolically stable and have a good pharmacokinetic and
toxicological proﬁle. Importantly, the lead compound 42a
demonstrates equipotent activity against all drug sensitive and
multidrug resistant strains of Mtb tested. Work continues to
develop a suitable pro-drug to embark on in vivo eﬃcacy studies.
■ EXPERIMENTAL SECTION
Chemistry. All reactions that employed moisture sensitive reagents
were performed in dry solvent under an atmosphere of nitrogen in oven-
dried glassware. All reagents were purchased from Sigma-Aldrich or Alfa
Aesar chemical companies and were used without puriﬁcation.
Thin layer chromatography (TLC) was carried out on Merck silica gel
60 F-254 plates, and UV inactive compounds were visualized using
iodine or anisaldehyde solution. Flash column chromatography was
performed on ICN Ecochrom 60 (32−63 mesh) silica gel eluting with
various solvent mixtures and using an air line to apply pressure. NMR
spectra were recorded on a Bruker AMX 400 (1H, 400 MHz; 13C,
100 MHz) spectrometer. Chemical shifts are described on parts per
million (δ) downﬁeld from an internal standard of trimethylsilane.
Mass spectra were recorded on a VG analytical 7070E machine and
Fisons TRIO spectrometers using electron ionization (EI) and chemical
Table 6. Yields for the Synthesis of Compounds 38a−l
Scheme 9. Synthesis of Compounds 39a−c
Scheme 10. Synthesis of Quinolones 42a−ba
aConditions and reagents: (a) CuI, N,N-dimethyl-1,2-diaminoethane, NaI, 1,4-dioxane, 110 °C, 24 h; (b) Pd2(dba)3, Xantphos, NaO
tBu, 1,4-dioxane,
110 °C, 24 h; (c) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
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ionization (CI). The optical rotation of the products were determined
on PerkinElmer Polarimeter (model 343Plus), and data was collected
and processed by Expert Read 1.00.02 software. All compounds
were found to be >95% pure by HPLC unless speciﬁed below.
See Supporting Information for experimental methods and data relating
to all intermediates.
Purity determination was performed by HPLC analysis using Agilent
1200 solvent delivery system. The HPLC methods used the following
conditions: Knauer Eurospher 100-5 C18 (250 mm × 4.6 mm) at 25 °C
with 1.5 mL/min ﬂow rate. Method A: 90% acetonitrile containing
0.05% triﬂuoroacetic acid and 10% water containing 0.05% triﬂuoro-
acetic acid. Method B: 80% methanol and 20% acetonitrile.
General Procedure for the Preparation Quinolones 1, 2, 7a−k,
17a−l, 21a−g, 24, 32a−g, 38a−j, 42a−b, and 45a−g. Triﬂuor-
omethanesulfonic acid (26 μL, 0.31 mmol, 0.2 equiv) was added to
oxazoline 4 (1.54 mmol) and the respective ketone (1.54 mmol, 1eq) in
anhydrous n-butanol (10 mL). The mixture was heated to 130 °C for
24 h (followed by TLC). The reaction was cooled and the solvent
removed under reduced pressure. Satd NaHCO3 (aq) was added and
the resulting aqueous solution was extracted with ethyl acetate (×3), the
combined organic layers were washed with water and brine, dried over
MgSO4, ﬁltered, and concentrated to a yellow solid. The crude product
was triturated with diethyl ether to give the desired quinolone. In cases
where trituration was not possible, compounds were puriﬁed by ﬂash
column chromatography.
Preparation of 3-Methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-
4(1H)-one 1. Light-yellow powder (yield 23%); mp 290−292 °C.
1H NMR (400 MHz, CDCl3) δH 8.46 (s, 1H, NH), 8.35 (d, 1H, J =
8.1 Hz, Ar), 7.59−7.52 (m, 1H, Ar), 7.36 (d, 2H, J = 8.7 Hz, Ar), 7.30
(dd, 2H, J = 15.1 H, 7.2 Hz, Ar), 6.96 (d, 2H, J = 8.7 Hz, Ar), 2.10 (3H·
CH3), 1.78−1.61 (m, 10H, CH2). 13C NMR (100 MHz, CDCl3) δC
179.1, 152.9, 148.0, 139.4, 131.8, 129.9, 126.7, 125.5, 124.0, 123.5, 117.4,
116.5, 115.6, 50.0, 26.0, 13.0. MS (ES+), [M +H]+ (100), 319.2. HRMS
calculated for 319.1810 C21H23N2O, found 319.1808. Anal.: C21H22N2O
requires C 79.21%, H 6.96%, N 8.80%. Found: C 78.83%, H 6.85%,
N 8.42%.
Preparation of 7-Methoxy-3-methyl-2-(4-(piperidin-1-yl)phenyl)-
quinolin-4(1H)-one 2. Orange powder (yield 36%); mp 278−280 °C.
1H NMR (400 MHz, CDCl3) δH 10.09 (s, 1H, NH), 8.16 (d, 1H, J =
8.5 Hz, Ar), 7.39 (d, 2H, J 0 8.9 Hz, Ar), 7.10 (d, 2H, J = 8.9 Hz, Ar), 6.92
(dd, 2H, J = 8.5 Hz, 2.6 Hz, Ar), 3.89 (s, 3H, OCH3), 3.33−3.28 (m, 2H,
CH2), 2.06 (s, 3H, CH3), 1.80−1.61 (m, 6H, CH2). 13C NMR
(100 MHz, CDCl3) δC 176.4, 161.8, 152.8, 129.5, 126.5, 124.7, 115.3,
114.7, 114.3, 97.7, 54.7, 25.3, 24.1, 11.4. MS (ES+), [M + H]+ (100),
348.2. HRMS calculated for 348.1916 C22H25N3O, found 348.2002.
Scheme 11. Synthesis of Quinolones 45a−ga
aConditions and reagents: (a) D-proline, CuI, K2CO3, DMF, 140 °C, 24 h; (b) (i) EDC, N-hydroxysuccinamide, CHCl3, NEt3, amine, rt, 6 h,
(ii) amine, NEt3, rt, 2 h; (c) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
Table 7. Yields for the Synthesis of Compounds 45a−g
aAlternative methodology used please see Supporting Information. bUsed crude.
Scheme 12. Synthesis of Pro-drug 46a
a(a) (i) tBuOK, THF, rt, 1 h, (ii) acetyl chloride, rt, 3 h.
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Anal.: C22H24N2O2 requires C 75.83%, H 6.94%, N 8.04%. Found:
C 75.47%, H 6.83%, N 7.61%.
Preparation of 6-Fluoro-3-methyl-2-(4-(piperidin-1-yl)phenyl)-
quinolin-4(1H)-one 7a. Orange powder (yield 26%); mp 328−
330 °C. 1H NMR (400 MHz, DMSO) δH 11.53 (s, 1H, NH), 7.71
(ddd, 1H, J = 13.9 Hz, 9.3 Hz, 3.9 Hz, Ar), 7.51 (ddd, 1H, J = 9.1 Hz,
8.4Hz, 3.0Hz, Ar), 7.38 (d, 2H, J = 8.9Hz, Ar), 7.07 (d, 2H, J = 8.9Hz, Ar),
3.30−3.26 (m, 4H, CH2), 1.95 (s, 3H, CH3), 1.66−1.55 (m, 6H, CH2).
13C NMR (100 MHz, DMSO) δC 176.2, 157.1, 152.2, 148.6, 136.6,
130.2, 124.3, 121.2, 120.4, 115.0, 113.9,109.1, 49.1, 25.3, 24.3, 12.8. MS
(ES+), [M + H]+ (100), 337.2. HRMS calculated for 337.1716
C21H22N2OF, found 337.1728. Anal.: C21H21N2OF requires C 74.98%,
H 6.29%, N 8.33%. Found: C 74.51%, H 6.07%, N 8.04%.
Preparation of 6,7-Dimethoxy-3-methyl-2-(4-(piperidin-1-yl)-
phenyl)quinolin-4(1H)-one 7b. Very pale-yellow solid (yield 28%).
1H NMR (400 MHz, DMSO) δH 11.24 (s, 1H, NH), 7.45 (s, 1H, Ar),
7.36 (d, J = 8.8Hz, 2H, Ar), 7.16−6.98 (m, 3H, Ar), 3.83 (s, 3H, OCH3),
3.82 (s, 3H, OCH3), 3.29−3.25 (m, 4H, CH2), 1.93 (s, 3H, CH3), 1.69−
1.53 (m, 6H, CH2).
13C NMR (101 MHz, DMSO) δC 175.90 (CO),
152.89, 152.05, 146.82, 146.54, 135.51, 130.19, 124.73, 117.34, 114.98,
113.15, 104.50, 99.38, 55.86 (OCH3), 55.79 (OCH3), 49.20, 25.35,
24.32, 12.86 (CH3). HRMS (ESI) C23H27N2O3 [M + H]
+ requires
379.2022, found 379.2012 (100%). Anal.: C23H26N2O3 requires C
72.99%, H 6.92%, N 7.40%. Found: C 71.98%, H 6.96%, N 6.96%.
Preparation of 6-Chloro-7-methoxy-3-methyl-2-(4-(piperidin-1-
yl)phenyl)quinolin-4(1H)-one 7c. White solid (yield 35%); mp
>300 °C. 1H NMR (400 MHz, DMSO) δH 11.42 (s, 1H, NH), 8.02
(s, 1H, Ar), 7.38 (d, J = 8.8 Hz, 2H, Ar), 7.21 (s, 1H, Ar), 7.07 (d, J =
8.9 Hz, 2H, Ar), 3.91 (s, 3H, OCH3), 3.31−3.22 (m, 4H, CH2), 1.93
(s, 3H, CH3), 1.71−1.52 (m, 6H, CH2). 13C NMR (101 MHz, DMSO)
δC 175.63 (CO), 156.74, 152.17, 148.16, 140.13, 130.21, 126.09,
Table 8. Mtb IC50 Values for Compounds 1, 2, 7a−k, 14a−c,
and 15a−f
compd X Y R Mtb IC50 (μM)
1 H Me H 1.50 ± 0.19
2 7-OMe Me H 0.73 ± 0.01
7a 6-F Me H 1.83 ± 0.22
7b 6-OMe, 7-OMe Me H >10
7c 6-Cl, 7-OMe Me H >10
7d 6-F, 7-OMe Me H 0.52 ± 0.06
7e 5-OMe, 7-OMe Me H >10
7f 5-F, 7-F Me H 0.27 ± 0.08
7g 7-F Me H >10
7h 7-Cl Me H >10
7i H Me F >10
7j 7-OMe Me F 1.32 ± 0.10
7k 5-F, 7-F Me F 0.94 ± 0.12
14a H H H >10
14b 7-OMe H H >10
14c 7-OMe H F >10
15a H Cl H 1.56 ± 0.22
15b 7-OMe Cl H 2.82 ± 0.21
15c 7-OMe Cl F >10
15d H Cl F >10
15e H Br H 0.60 ± 0.09
15f H Br F >10
Table 9. Mtb IC50 Values for Compounds 17a−l and 24
Table 10. Mtb IC50 Values for Compounds 21a−g
compd X A B Mtb IC50 (μM)
21a H CH CH2Ph >10
21b 6-F CH CH2Ph >10
21c 7-OMe CH CH2Ph >10
21d H N CH2Ph 5.74 ± 0.66
21e 6-F N CH2Ph >10
21f 7-OMe N Ph >10
21g 7-OMe N CH2Ph >10
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124.18, 118.08, 117.91, 114.89, 114.25, 100.13, 56.59 (OCH3), 49.10,
25.32, 24.32, 12.70 (CH3). HRMS (ESI) C22H24N2O2
35Cl [M + H]+
requires 383.1526, found 383.1513 (100%), C22H24N2O2
37Cl [M + H]+
requires 385.1497, found 385.1501 (34%). Anal.: C22H23N2O2Cl
Table 11. Mtb IC50 Values for Compounds 32a−g, 38a−j, 39a−c, 42a−b, and 45a−g
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requires C 69.01%, H 6.05%, N 7.32%. Found: C 68.98%, H 6.04%,
N 7.23%.
Preparation of 6-Fluoro-7-methoxy-3-methyl-2-(4-(piperidin-1-
yl)phenyl)quinolin-4(1H)-one 7d. White solid (yield 41%). 1H NMR
(400MHz, DMSO) δH 11.39 (s, 1H, NH), 7.71 (d, J = 11.9 Hz, 1H, Ar),
7.37 (d, J = 8.7 Hz, 2H, Ar), 7.24 (d, J = 7.5 Hz, 1H, Ar), 7.07 (d, J =
8.8 Hz, 2H, Ar), 3.90 (s, 3H, OCH3), 3.30−3.19 (m, 4H, CH2), 1.92
(s, 3H, CH3), 1.74−1.48 (m, 6H, CH2). 13C NMR (101 MHz, DMSO)
δC 175.94 (CO), 152.15, 151.00, 150.87, 150.35, 147.88, 137.55,
130.20, 124.30, 114.93, 113.57, 110.03, 101.12, 56.36 (OCH3),
49.13, 25.33, 24.32, 12.70 (CH3). HRMS (ESI) C22H24N2O2F
[M + H]+ requires 367.1822, found 367.1818. Anal.: C22H23N2O2F
requires C 72.11%, H 6.33%, N 7.64%. Found: C 71.95%, H 6.45%,
N 7.37%.
Preparation of 5,7-Dimethoxy-3-methyl-2-(4-(piperidin-1-yl)-
phenyl)quinolin-4(1H)-one 7e. White solid (yield 32%); mp 264−
265 °C. 1HNMR (400MHz, DMSO) δH 10.93 (s, 1H, NH), 7.33 (d, J =
8.7 Hz, 2H, Ar), 7.05 (d, J = 8.7 Hz, 2H, Ar), 6.64 (d, J = 2.2 Hz, 1H, Ar),
6.25 (d, J = 2.1 Hz, 1H, Ar), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3),
3.32−3.11 (m, 4H, CH2), 1.82 (s, 3H, CH3), 1.70−1.48 (m, 6H, CH2).
13C NMR (101 MHz, DMSO) δC 176.49 (CO), 161.75, 161.03,
152.02, 145.53, 143.94, 130.15, 124.47, 115.49, 114.98, 109.24, 94.23,
91.57, 55.97 (OCH3), 55.48 (OCH3), 49.22, 25.35, 24.32, 12.82 (CH3).
HRMS (ESI) C23H27N2O2 [M + H]
+ requires 379.2022, found
379.2007. Anal.: C23H26N2O2 requires C 72.99%, H 6.92%, N 7.40%.
Found: C 72.13%, H 6.88%, N 7.03%.
Preparation of 5,7-Diﬂuoro-3-methyl-2-(4-(piperidin-1-yl)-
phenyl)quinolin-4(1H)-one 7f. Oﬀ-white solid (0.25 g, 35%); mp
305−306 °C. 1H NMR (400 MHz, DMSO) δ 11.50 (bs, 1H), 7.37
(d, J = 8.8 Hz, 2H), 7.15 (d, J = 9.2 Hz, 1H), 7.08 (d, J = 8.9 Hz, 2H),
6.98 (t, J = 9.6 Hz, 1H), 3.30 (m, 4H), 1.88 (s, 3H), 1.61 (m, 6H). 13C
NMR (100 MHz, CDCl3) δC 175.2, 152.1, 148.6, 130.2, 116.1, 114.9,
100.2, 49.2, 25.3, 24.3, 12.6. MS (ES+) m/z 355 (M + H)+. HRMS
calculated for 355.1622 C21H21N2OF2, found 355.1625. Purity HPLC
95% (method A) Rt = 2.34 min.
Preparation of 7-Fluoro-3-methyl-2-(4-(piperidin-1-yl)phenyl)-
quinolin-4(1H)-one 7g. Oﬀ-white solid (0.15 g, 35%); mp 343−
345 °C. 1H NMR (400 MHz, DMSO) δ 8.14 (dd, J = 9.0, 6.6 Hz, 1H),
7.38 (d, J = 8.8 Hz, 2H), 7.30 (dd, J = 10.5, 2.3 Hz, 1H), 7.10 (m, 1H),
7.05 (d, J = 8.8 Hz, 2H), 3.28 (m, 4H), 1.94 (s, 3H), 1.62 (m, 6H). 13C
NMR (100MHz, DMSO) δC not soluble in DMSO. MS (ES
+)m/z 337
(M + H)+. HRMS calculated for 337.1716 C21H22N2OF, found
337.1722. Purity HPLC 97% (method B) Rt = 2.44 min.
Preparation of 7-Chloro-3-methyl-2-(4-(piperidin-1-yl)phenyl)-
quinolin-4(1H)-one 7h. Oﬀ-white solid (0.17 g, 37%); mp 342−
343 °C. 1HNMR (400MHz, DMSO) δ 8.08 (d, J = 8.7 Hz, 1H), 7.59 (s,
1H), 7.40 (d, J = 8.8 Hz, 2H), 7.18 (dd, J = 8.7, 2.0 Hz, 1H), 7.04 (d, J =
8.8 Hz, 2H), 3.08 (m, 4H), 1.95 (s, 3H), 1.61 (m, 6H). 13C NMR
(100 MHz, CDCl3) δC not soluble in DMSO. MS (ES
+) m/z 353
(M + H)+. HRMS calculated for 353.1425 C21H22N2O
35Cl, found
353.1421. Purity HPLC 97% (method A) Rt = 2.07 min.
Preparation of 2-(4-(4-Fluoropiperidin-1-yl)phenyl)-3-methylqui-
nolin-4(1H)-one 7i. White solid (0.18 g, 36%). 1H NMR (400 MHz,
DMSO) 8.10 (d, J = 8.8 Hz, 1H), 7.57 (m, 2H), 7.40 (d, J = 8.8 Hz, 2H),
7.24 (dd, J = 7.2, 6.8 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 4.88 (d, J =
48.8 Hz, 1H), 3.24 (m, 4H), 2.03 (m, 2H), 1.95 (s, 3H), 1.80 (m, 2H).
13C NMR (100 MHz, DMSO) δC 176.4, 150.7, 130.6, 130.0, 124.9,
123.3, 122.1, 119.0, 114.8, 113.8, 89.4, 87.8, 44.6, 44.5, 30.5, 30.3,
12.6. MS (ES+) m/z 337 (M + H)+. HRMS calculated for 337.1716
C21H22N2OF, found 337.1720. Purity HPLC 96% (method A) Rt =
2.21 min.
Preparation of 2-(4-(4-Fluoropiperidin-1-yl)phenyl)-7-methoxy-3-
methylquinolin-4(1H)-one 7j. Yellow solid (yield 43%). 1H NMR
(400 MHz, DMSO) δ 11.26 (s, 1H, NH), 8.00 (d, J = 8.9 Hz, 1H, Ar),
7.39 (d, J = 8.6 Hz, 2H, Ar), 7.12 (d, J = 8.6 Hz, 2H, Ar), 7.05 (d, J =
2.1 Hz, 1H, Ar), 6.88 (dd, J = 8.9, 2.2 Hz, 1H, Ar), 5.02−4.77 (m, 1H,
CH), 3.82 (s, 3H, OCH3), 3.57−3.44 (m, 2H, CH2), 3.32−3.20 (m, 2H,
CH2), 2.13−1.95 (m, 2H, CH2), 1.91 (s, 3H, CH3), 1.86−1.71 (m, 2H,
CH2).
13C NMR (101MHz, DMSO) δ 176.78 (CO), 161.89, 151.28,
147.80, 141.66, 130.39, 127.22, 125.12, 117.98, 115.22, 114.02, 113.14,
99.23, 89.01 (d, J = 169.4 Hz, C−F), 55.74, 44.87 (d, J = 6.8 Hz), 30.84
(d, J = 19.0 Hz), 12.78 (CH3). HRMS (ESI) C22H24N2O2F [M + H]
+
requires 367.1822, found 367.1836. Anal.: C22H23N2O2F requires C
72.11%, H 6.33%, N 7.64%. Found: C 71.32%, H 6.34%, N 7.46%.
Preparation of 5,7-Diﬂuoro-2-(4-(4-ﬂuoropiperidin-1-yl)phenyl)-
3-methylquinolin-4(1H)-one 7k. White solid (29%); mp >320 °C. 1H
NMR (400 MHz, DMSO) 11.51 (s, 1H), 7.40 (m, 2H), 7.15 (m, 3H),
7.00 (m, 1H), 3.49 (m, 2H), 3.24 (m, 2H), 2.0 (m, 2H), 1.89 (s, 3H),
1.75 (m, 2H). 13C NMR (100 MHz, DMSO) δC not soluble in
DMSO. MS (ES+) m/z 373 (M + H)+ HRMS calculated for 373.1519
C21H20N2OF3, found 373.7528. Purity HPLC 97% (method A) Rt =
2.18 min.
Figure 5. Overall SAR trends for the heterocyclic quinolone series.
Table 12. HEPG2 and Microsomal Turnover t1/2 for Selected
Analogues
compd Mtb IC50 (μM)
Mtb
IC90
(μM)
HEPG2
GLU
(μM)
therapeutic
index
microsomal
turnover (h, m,
r) t1/2 (min)
7f 0.270 ± 0.080 0.78 >100 >370 h, 7.31
m, 8.27
r, 8.30
7k 0.950 ± 0.120 1.83 102.2 108 h, 5.7
m, 4.4
r, 8.4
17b 0.611 ± 0.048 1.93 >100 >164 h, <10
m, <10
r, <10
17e 0.300 ± 0.025 0.56 188.1 627 h, 7.8
m, 6.8
r, 10.1
17f 0.367 ± 0.040 0.63 >100 >272 h, 7.9
m, 22.3
r, 10.8
17h 0.400 ± 0.023 0.66 85.54 223 h, 8.54
m, 7.65
r, 5.72
32e 0.432 ± 0.020 0.69 141 342 h, 10.2
m, 20.7
r, 30.1
38a 0.231 ± 0.036 0.50 150.6 649 h, 10.2
m, 4.4
r, 10.6
38d >10 >10 ND ND h, 60
m, 60
r, 60
42a 0.525 ± 0.080 1.10 >100 >190 h, 72.8
m, 114.9
r, 61.6
42b 0.361 ± 0.041 0.83 ND ND h, 17.4
m, 16.2
r, 13.7
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General Procedure for the Preparation of Compounds 14a−c. To
a solution of ketone 13 (0.24 mmol) in anhydrous 1,4-dioxane (8 mL)
was added ground sodium hydroxide (30 mg, 0.75 mmol, 3 equiv). The
mixture was allowed to reﬂux at 110 °C for 5 h. The solution was cooled
to room temperature and acidiﬁed by addition of 2N hydrochloric acid.
The solid was ﬁltered and washed with water, followed by ethyl acetate
and dried.
Preparation of 2-(4-(Piperidin-1-yl)phenyl)quinolin-4(1H)-one
14a. White solid (0.25 g, 70%); mp 350 °C. 1H NMR (400 MHz,
DMSO) δ 11.42 (bs, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.76 (d, J =
8.3 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.64 (dd, J = 8.3, 7.0 Hz, 1H),
7.30 (dd, J = 8.3, 7.0 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.29 (s, 1H),
3.33 (m, 4H), 1.19 (m, 6H). 13C NMR (100 MHz, DMSO) δC
not soluble in DMSO. MS (ES+) m/z 305 (M + H)+. HRMS calcu-
lated for 305.1654 C20H21N2O, found 305.1662. Anal.: C20H20N2O
requires C 78.92%, H 6.62%, N 9.20%. Found: C 78.67%, H 6.55%,
N 8.89%.
Figure 6. Resolution of metabolic stability problems.
Table 13. Caco-2 Permeability, Stability in Plasma, % PPB,
and Solubility Values for Selected Analogues
solubility (μg/mL)
compd
Caco-2
permeability
(cm−1/s)
stability in
plasma (r, h)
T1/2 (min)
human
PPB
(%) pH 1 pH 7.4 CMa
5k ND r, >180 95.82 >150 <1 12
h, >180
17e 22.86 × 10−6 r, >180 98.45 >150 <1 10
h, >180
32e 30.97 × 10−6 r, >180 96.1 5.1 3.6 61
h, >180
38b 15.51 × 10−6 r, >180 98.97 <1 <1 2.5
h, >180
42a 10.00 × 10−6 r, >180 97.30 <1 <1 55
h, >180
aCM, culture media: Middlebrook 7H9 broth with addition of 10%
albumin−dextrose−catalase solution (Becton Dickinson), 0.2% [vol/
vol] glycerol, and 0.05% [vol/vol] Tween 80.
Table 14. In Vitro DMPK Measurements for Selected
Analogues
compd
aq
solubility
(μM)
human
% PPB LogD7.4
human
microsomes
CLint
(μL/min/mg)
rat hepatocytes
CLint
(μL/min/106
cells)
7d 2 98.8 3.9 >300.0 231.3
15b 0.5 98.8 3.6 >300.0 48.9
17g <0.5 99.5 4.7 >300.0 183.4
17h <0.3 99.3 >3.2 >300.0 91.2
17j <0.1 99.4 4.8 >300.0 243.4
38a 0.9 99.1 3.8 174.9 117.6
38b 1 98.6 3.6 197.4 150.1
39a 4 95.5 >3.4 >300.0 36.5
39b 4 95.5 >3.4 >300.0 36.5
42a 0.2 99.7 4 89.7 52.2
Table 15. Biological Proﬁle of 42a
42a
In Vitro Antituberculosis Activity
replicating sensitive Mtb IC50 (μM) 0.525
replicating sensitive Mtb IC90 (μM) 1.10
dormant (Wayne model) Mtb IC90 (μM) 0.076
MDR Mtb (05TB42059) IC50 (μM) 0.140
MDR Mtb (DQ707(S315N kat G)) IC50 (μM) 0.548
In Vitro DMPK
microsomal turnover (h, m, r) T1/2 (min) h, 72.8; m, 114.9; r, 61.6
microsomal Clint (h, m, r) (μL/min/mg) h, 9.52; m, 6.03; r, 11.25
Caco-2 permeability (cm−1/s) A to B 10.00 × 10−6
Caco-2 permeability (cm−1/s) B to A 9.8 × 10−6
stability in plasma (r, h) T1/2 (min) r, >180; h, >180
human % PPB 97.30
solubility (μg/mL) pH1, pH7.4, CM <1, <1, 55
CYP2C8 inhibition (% at 10 μM) 38
CYP2C9 inhibition (% at 10 μM) 0
CYP2D6 inhibition (% at 10 μM) 0
CYP3A4 inhibition (% at 10 μM) 0
CYP3A5 inhibition (% at 10 μM) 0
In Vitro Toxicity
HEPG2 IC50 GLU (μM) >100
TI >190
hERG IC50 (μM) >25
Ames −ve
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Preparation of 7-Methoxy-2-(4-(piperidin-1-yl)phenyl)quinolin-
4(1H)-one 14b. White solid (0.065 g, 41%); mp 350 °C. 1H NMR
(400 MHz, DMSO) δ 11.30 (bs, 1H), 7.96 (d, J = 8.9 Hz, 1H), 7.69
(d, J = 8.7 Hz, 2H), 7.23 (d, J = 2.3 Hz, 1H), 7.07 (d, J = 8.9 Hz, 2H),
6.89 (dd, J = 8.0, 4.0 Hz, 1H), 6.21 (s, 1H), 3.86 (s, 3H), 3.34 (m, 4H),
1.60 (m, 6H). 13CNMR (100MHz, DMSO) δC not soluble inDMSO.MS
(ES+) m/z 335 (M + H)+. HRMS calculated for 335.1760 C21H23N2O2,
found 335.1761. Purity HPLC 96% (method A) Rt = 1.81 min.
Preparation of 2-(4-(4-Fluoropiperidin-1-yl)phenyl)-7-methoxy-
quinolin-4(1H)-one 14c. Yellow solid (yield 68%). 1H NMR
(400 MHz, DMSO) δH 13.70 (s, 1H, NH), 8.18 (d, J = 9.2 Hz, 1H,
Ar), 7.88 (d, J = 9.0 Hz, 2H, Ar), 7.58 (d, J = 2.3 Hz, 1H, Ar), 7.34
(dd, J = 9.2, 2.4 Hz, 1H, Ar), 7.31−7.19 (m, 3H, Ar), 4.93 (dtt, J = 48.9,
7.0, 3.4 Hz, 1H, CH), 3.98 (s, 3H, OCH3), 3.71−3.58 (m, 2H, CH2),
3.51−3.37 (m, 2H, CH2), 2.10−1.88 (m, 2H, CH2), 1.87−1.68 (m, 2H,
CH2). HRMS (ESI) C21H22N2O2F [M + H]
+ requires 353.1665, found
353.1667. Anal.: C21H21N2O2F requires C 71.57%, H 6.01%, N 7.95%.
Found: C 71.12%, H 5.93%, N 7.71%.
General Procedure for the Preparation of Compounds 15a−d.
Quinolone 14 (0.33 mmol) was added to MeOH (20 mL), 2 M NaOH
(4 mL), and water (4 mL). Sodium dichloroisocyanurate (36 mgs, 0.17
mmol, 0.5 equiv) was added at room temperature, and the resultant
light-orange solution was allowed to stir overnight. The solvent was
removed in vacuo and the residue was dissolved in EtOAc (100 mL),
followed by washing with water (50 mL) and brine (50 mL). The crude
product was puriﬁed by column chromatography (eluting with 100%
EtOAc) to aﬀord the desired product.
Preparation of 3-Chloro-2-(4-(piperidin-1-yl)phenyl)quinolin-
4(1H)-one 15a. White solid (40 mgs, 40%). 1H NMR (400 MHz,
DMSO) δ 12.01 (bs, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.69 (m 2H), 7.52
(d, J = 8.7 Hz, 2H), 7.38 (m, 1H), 7.09 (d, J = 8.8 Hz, 2H), 3.33 (m, 4H),
1.61 (m, 6H). 13C NMR (100 MHz, DMSO) δC 171.7, 152.5, 148.7,
139.3, 132.2, 130.7, 125.4, 124.0, 123.8, 122.1, 118.9, 114.5, 113.2, 48.9,
25.3, 24.3. MS (ES+)m/z 339 (M +H)+ HRMS calculated for 339.1264
C20H20N2O
35Cl, found 339.1252. Purity HPLC 98% (method A) Rt =
2.13 min.
Preparation of 3-Chloro-7-methoxy-2-(4-(piperidin-1-yl)phenyl)-
quinolin-4(1H)-one 15b. White solid (27 mgs, 61%). 1H NMR
(400 MHz, DMSO) δ 11.82 (bs, 1H), 8.04 (d, J = 9.0 Hz, 1H), 7.52
(d, J = 8.8 Hz, 2H), 7.11 (m, 3H), 6.99 (dd, J = 9.2, 2.4 Hz, 1H), 3.85
(s, 3H), 3.33 (m, 4H), 1.61 (m, 6H). 13C NMR (100 MHz, DMSO) δC
162.3, 148.1, 141.1, 130.6, 127.3, 118.2, 114.7, 114.2, 112.9, 99.7, 55.8,
49.1, 25.2, 24.2. MS (ES+) m/z 369 (M + H)+ HRMS calculated for
369.1370 C21H22N2O2
35Cl, found 369.1375. Purity HPLC 99%
(method A) Rt = 1.83 min.
Preparation of 3-Chloro-2-(4-(4-ﬂuoropiperidin-1-yl)phenyl)-7-
methoxyquinolin-4(1H)-one 15c. Yellow solid (yield 52%); mp
304−306 °C. 1H NMR (400 MHz, DMSO) δH 11.86 (s, 1H, NH),
8.03 (d, J = 9.0 Hz, 1H, Ar), 7.52 (d, J = 8.8 Hz, 2H, Ar), 7.14 (d, J =
8.9 Hz, 2H, Ar), 7.10 (d, J = 2.3 Hz, 1H, Ar), 6.98 (dd, J = 9.0, 2.4 Hz,
Figure 7. Pharmacokinetics after oral dosing of 42a (a), 46 (b), and an overlay of both (c).
Table 16. Pharmacokinetic Parameters for 42a and 46
parent 42a pro-drug 46a
dose (mg/kg) 0.5 (iv) 10 (po) 50 (po) 10 (po) 50 (po)
T1/2 (h) 1.48 3.8 4.2 3.9 2.3
CL (L/h/kg) 0.524
Vss (L/kg) 0.291
Cmax (μg/mL) 0.61 1.4 1.7 4.0
AUC (mg·h/L) 0.964 5.4 16.5 12.3 29.6
oral bioavailability (% F) N/A 28.0 17.1 63.8 30.7
aThese two studies were dosed with prodrug 46 orally, and measured
for the parent 42a in plasma.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01718
J. Med. Chem. 2017, 60, 3703−3726
3717
1H, Ar), 4.90 (dtt, J = 21.4, 7.3, 3.6 Hz, 1H, CH), 3.84 (s, 3H, OCH3),
3.63−3.46 (m, 2H), 3.34−3.19 (m, 2H), 2.13−1.90 (m, 2H), 1.85−1.58
(m, 2H). 13C NMR (101 MHz, DMSO) δC 171.31 (CO), 162.33
(C−O), 151.61, 148.08, 141.06, 130.67, 127.30, 122.71, 118.20, 114.66,
114.20, 112.89, 99.63, 88.89 (d, J = 169.5 Hz, C−F), 55.81, 44.53 (d, J =
6.8 Hz), 30.69 (d, J = 19.1 Hz). HRMS (ESI) C21H21N2O2F
35Cl
[M + H]+ requires 387.1276, found 387.1287. Anal.: C21H20N2O2FCl
requires C 65.20%, H 5.21%, N 7.24%. Found: C 64.90%, H 5.35%,
N 6.95%.
Preparation of 3-Chloro-2-(4-(4-ﬂuoropiperidin-1-yl)phenyl)-
quinolin-4(1H)-one 15d. Light-yellow solid (0.19 g, 58%). 1H NMR
(400MHz, DMSO) 12.05 (bs, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.70 (d, J =
4.0 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.38 (m, 1H), 7.15 (d, J = 8.8 Hz,
2H), 4.89 (d, J = 48.0 Hz, 1H), 3.53 (m, 2H), 3.30 (m, 2H), 1.97 (m,
2H), 1.79 (m, 2H). 13C NMR (100 MHz, DMSO) δC 175.2, 150.8,
128.5, 127.9, 127.3, 124.6, 115.4, 103.9, 89.9, 88.2, 79.6, 66.7, 45.2, 45.1,
31.0, 30.8, 15.5. MS (ES+) m/z 357 (M + H)+. HRMS calculated for
357.1170 C20H19N2OF
35Cl, found 357.1159. Purity HPLC 95%
(method A) Rt = 2.15 min.
General Procedure for the Preparation of Compounds 15e−f.
Quinolone 14 (0.33 mmol) was added to DCM (15 mL) and MeOH
(4 mL). NBS (58 mgs, 0.33 mmol) was added at room temperature, and
the resultant bright-yellow solution was allowed to stir overnight.
The solvent was removed in vacuo, and the residue was dissolved in
EtOAc (100 mL), followed by washing with water (50 mL) and brine
(50 mL). The crude product was puriﬁed by column chromatography
(eluting with 70% EtOAc in n-hexanes) to aﬀord the desired product.
Preparation of 3-Bromo-2-(4-(piperidin-1-yl)phenyl)quinolin-
4(1H)-one 15e. White solid (63%). 1H NMR (400 MHz, DMSO) δ
12.07 (bs, 1H), 8.15 (d, J = 8.1Hz, 1H), 7.68 (m 2H), 7.49 (d, J = 8.8Hz,
2H), 7.39 (ddd, J = 8.6, 7.9, 4.1 Hz, 1H), 7.08 (d, J = 8.8 Hz, 2H), 3.31
(m, 4H), 1.62 (m, 6H). 13C NMR (100 MHz, DMSO) δC 172.1, 152.5,
150.4, 139.4, 132.3, 130.6, 125.6, 124.2, 124.0, 123.2, 118.8, 114.5, 105.5,
49.0, 25.3, 24.4. MS (ES+) m/z 383 (M + H)+. HRMS calculated
for 383.0759 C20H20N2O
79Br, found 383.0748. Purity HPLC 98%
(method A) Rt = 1.75 min.
Preparation of 3-Bromo-2-(4-(4-ﬂuoropiperidin-1-yl)phenyl)-
quinolin-4(1H)-one 15f. Light-yellow solid (0.20 g, 55%). 1H NMR
(400 MHz, DMSO) 12.26 (bs, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.69
(m, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.39 (m, 2H), 7.14 (d, J = 8.8 Hz, 2H),
4.89 (d, J = 48.0 Hz, 1H), 3.53 (m, 2H), 3.30 (m, 2H), 1.97 (m, 2H),
1.79 (m, 2H). 13CNMR (100MHz, DMSO) δC 179.7, 150.3, 132.3, 130.2,
125.6, 124.5, 114.6, 105.6, 89.7, 88.1, 44.6, 44.5, 30.8, 15.5. MS (ES+) m/z
401 (M + H)+. HRMS calculated for 401.0665 C20H19N2OF
79Br, found
401.0656. Purity HPLC 99% (method A) Rt = 2.15 min.
Preparation of 5,7-Diﬂuoro-3-methyl-2-(4-(4-(triﬂuoromethyl)-
piperidin-1-yl)phenyl)quinolin-4(1H)-one 17a. White solid (32%);
mp >350 °C. 1HNMR (400MHz, DMSO) 11.52 (s, 1H), 7.39 (m, 2H),
7.17 (m, 3H), 7.00 (m, 1H), 3.95 (m, 2H), 2.85 (m, 2H), 1.91 (m, 2H),
1.87 (s, 3H), 1.55 (m, 2H). 13C NMR (100 MHz, DMSO) δC not
soluble in DMSO. MS (ES+) m/z 423 (M + H)+. HRMS calculated for
423.1496 C22H20N2OF5, found 423.1483. Anal.: C22H19N2OF5 requires
C 62.56%, H 4.53%, N 6.63%. Found: C 62.49%, H 4.52%, N 6.62%.
Preparation of 5,7-Diﬂuoro-3-methyl-2-(4-(4-methylpiperidin-1-
yl)phenyl)quinolin-4(1H)-one 17b. White solid (54%); mp decom-
posed at 310 °C. 1H NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 7.36 (d,
J = 8.8 Hz, 2H), 7.16 (d, J = 10.0 Hz, 1H), 7.08 (d, J = 8.9 Hz, 2H), 7.00
(ddd, J = 12.0, 9.6, 2.4 Hz, 1H), 3.83 (d, J = 12.8 Hz, 2H), 2.76 (td, J =
12.5, 2.4 Hz, 2H), 1.87 (s, 3H), 1.70 (d, J = 12.7 Hz, 2H), 1.63−1.49 (m,
1H), 1.21 (qd, J = 12.7, 4.0 Hz, 2H), 0.94 (d, J = 6.5 Hz, 3H). 13C NMR
(101 MHz, DMSO) δ 175.37, 163.51, 160.76, 152.01, 147.65, 142.84,
130.21, 123.60, 116.33, 114.91, 110.49, 99.41, 98.81, 48.41, 33.55, 30.65,
22.18, 12.51. ES HRMS: m/z found 369.1792, C22H23N2OF2 requires
369.1778. Anal.: C22H22N2OF2 requires C 71.72%, H 6.02%, N 7.60%.
Found: C 71.66%, H 5.95%, N 7.52%.
Preparation of 2-(4-(6-Azaspiro[2.5]octan-6-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 17c. White solid (yield 34%);
mp >300 °C. 1H NMR (400 MHz, DMSO) δH 11.51 (s, 1H, NH), 7.38
(d, J = 8.7 Hz, 2H), 7.16 (d, J = 10.0 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H),
7.00 (ddd, J = 11.9, 9.6, 2.3 Hz, 1H), 3.38−3.35 (m, 4H), 1.88 (s, 3H,
CH3), 1.53−1.36 (m, 4H), 0.35 (s, 4H). 13C NMR (101 MHz, DMSO)
δC 175.52, 163.75 (d, J = 61.6 Hz), 161.38 (d, J = 77.0 Hz), 152.14,
Figure 8. Metabolic Pathways of Pro-drug 46 in SD Rat Urine and Bile.
Table 17. Identiﬁed Metabolites of Pro-drug 46 in SD Rat Urine and Bile (MS)
relative MS abundance
peak ID mass shift found m/z biotransformation RT (min) bile urine
46 0 419 parent 14.3 ND 1.85 × 1007
M1 −10 409 hydrolysis/hydroxylation 8.6 5.89 × 106 ND
M2 −10 409 hydrolysis/hydroxylation 9.2 4.21 × 106 ND
M3 −10 409 hydrolysis/hydroxylation 9.9 5.92 × 107 2.61 × 107
M4 −26 393 hydrolysis/hydroxylation 10.1 2.12 × 107 3.80 × 106
M5-42a −42 377 hydrolysis 11.4 5.36 × 106 6.12 × 106
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147.75, 142.80 (dd, J = 14.7, 6.3 Hz), 130.34, 123.72, 116.45, 115.22,
110.59 (d, J = 2.4 Hz), 99.60 (dd, J = 24.9, 4.1 Hz), 98.95 (dd, J = 28.7,
25.6 Hz), 48.40, 34.32, 18.15, 12.61, 11.59. HRMS (ESI)
C23H22N2OF
23Na [M + Na]+ requires 403.1598, found 403.1612.
Anal.: C23H22N2OF requires C 72.61%, H 5.83%, N 7.36%. Found: C
72.41%, H 5.91%, N 7.31%.
Preparation of 2-(4-(4,4-Diﬂuoropiperidin-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 17d. White solid (0.30 g, 57%).
1H NMR (400 MHz, DMSO) δH 7.38 (d, J = 8.8 Hz, 2H), 7.10 (d, J =
8.8 Hz, 2H), 7.07 (m, 1H), 6.82 (dd, J = 11.0, 10.6 Hz, 1H), 3.43 (m,
4H), 2.07 (m, 4H), 1.88 (s, 3H). 13C NMR (100 MHz, DMSO) δC
174.2, 149.5, 129.9, 122.8, 118.5, 115.3, 115.0, 45.3, 33.0, 32.8, 32.5,
12.6. MS (CI+) m/z 391 (M + H)+. HRMS calculated for 391.1428
C21H19N2OF4, found 391.1430. Purity HPLC 95% (method A) Rt =
2.39 min.
Preparation of 5,7-Diﬂuoro-2-(4-(3-ﬂuoropiperidin-1-yl)phenyl)-
3-methylquinolin-4(1H)-one 17e. Light-brown solid (0.12 g, 27%). 1H
NMR (400 MHz, DMSO) δH 11.49 (bs, 1H), 7.38 (d, J = 8.8 Hz, 2H),
7.10 (d, J = 8.8 Hz, 2H), 7.07 (m, 1H), 6.99 (dd, J = 11.0, 10.6 Hz,
1H),4.82 (d, J = 48.8 Hz, 1H), 3.50−3.33 (m, 4H), 1.87 (s, 3H), 1.86−
1.62 (m, 4H). 13C NMR (100 MHz, DMSO) δC 175.2, 151.4, 147.1,
129.8, 123.6, 116.0, 114.6, 98.8, 88.1, 86.4, 51.8, 51.6, 47.3, 29.3, 29.1,
20.6, 20.5, 12.1. MS (EI+) m/z 373 (M + H)+. HRMS calculated
for 373.1528 C21H20N2OF3, found 373.1524. Purity HPLC 97%
(method A) Rt = 2.42 min.
Preparation of 5,7-Diﬂuoro-3-methyl-2-(4-(3-methylpiperidin-1-
yl)phenyl)quinolin-4(1H)-one 17f. White solid (45%); mp 280−
282 °C. 1H NMR (400 MHz, DMSO) δH 11.50 (s, 1H), 7.36 (d, J =
8.8 Hz, 2H), 7.16 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 8.9 Hz, 2H), 7.00 (ddd,
J = 12.0, 9.6, 2.4 Hz, 1H), 3.77 (t, J = 11.6 Hz, 2H), 2.72 (td, J = 12.3,
2.9 Hz, 1H), 2.42 (dd, J = 12.4, 10.7 Hz, 1H), 1.87 (s, 3H), 1.82−
1.48 (m, 4H), 1.09 (ddd, J = 23.5, 12.4, 3.9 Hz, 1H), 0.93 (d, J = 6.6 Hz,
3H). 13C NMR (101 MHz, DMSO) δC 175.37, 164.10, 161.50, 152.00,
147.66, 142.69, 130.22, 123.46, 116.33, 114.81, 110.59, 99.40, 98.79,
55.93, 48.45, 32.93, 30.35, 24.72, 19.58, 12.50. ES HRMS: m/z found
369.1772, C22H23N2OF2 requires 369.1778. Anal.: C22H22N2OF2
requires C 71.72%, H 6.02%, N 7.60%. Found: C 71.76%, H 5.94%,
N 7.58%.
Preparation of (R)-5,7-Diﬂuoro-3-methyl-2-(4-(3-methylpiperidin-
1-yl)phenyl)quinolin-4(1H)-one 17g. White solid (43%). 1H and 13C
NMR data is the same as the racemic analogue. ES HRMS: m/z found
369.1775, C22H23N2OF2 requires 369.1778. Anal.: C22H22N2OF2
requires C 71.72%, H 6.02%, N 7.60%. Found: C 71.68%, H 6.06%,
N 7.53%. The optical rotation was measured as [α]D
22 = +81.5° ± 0.9
(c = 0.558 g/100 mL in MeOH).
Preparation of (S)-5,7-Diﬂuoro-3-methyl-2-(4-(3-methylpiperidin-
1-yl)phenyl)quinolin-4(1H)-one 17h. White solid (40%). 1H and
13C NMR data is the same as the racemic analogue. ES HRMS: m/z
found 369.1782, C22H23N2OF2 requires 369.1778. Anal.: C22H22N2OF2
requires C 71.72%, H 6.02%, N 7.60%. Found: C 71.77%, H 6.0%,
N 7.64%. The optical rotation was measured as [α]D
22 = −86.1° ± 0.7
(c = 0.588 g/100 mL in MeOH).
Preparation of 5,7-Diﬂuoro-3-methyl-2-(4-(4-methylpiperazin-1-
yl)phenyl)quinolin-4(1H)-one 17i. White solid (39%); mp >350 °C.
1H NMR (400 MHz, DMSO) δH 11.50 (s, 1H), 7.89 (d, J = 9.0, 2H),
7.19 (m, 1H), 7.05 (m, 1H), 6.85 (d, J = 9.0, 2H), 3.35 (m, 4H), 2.55
(m, 4H), 2.31 (s, 3H), 1.90 (s, 3H). 13C NMR (100 MHz, DMSO) δC
not soluble in DMSO. MS (ES+) m/z 370 (M + H)+. HRMS calcu-
lated for 370.1717 C21H22N3OF2, found 370.1731. Purity HPLC 99%
(method A) Rt = 1.59 min.
Preparation of 2-(4-(Azepan-1-yl)phenyl)-5,7-diﬂuoro-3-methyl-
quinolin-4(1H)-one 17j. White solid (41%); mp >350 °C. 1H NMR
(400 MHz, DMSO) δH 11.45 (s, 1H), 7.31 (d, J = 8.8, 2H), 7.19 (m,
1H), 7.00 (m, 1H), 6.85 (d, J = 8.9, 2H), 3.55 (m, 4H), 1.92 (s, 3H), 1.75
(bs, 4H), 1.45 (bs, 4H). 13C NMR (100 MHz, DMSO) δC 175.4, 149.4,
147.8, 130.5, 120.5, 116.1, 110.8, 99.54, 98.9, 98.7, 49.1, 48.1, 47.9, 47.7,
47.5, 27.0, 26.6, 12.6. MS (ES+) m/z 369 (M + H)+. HRMS calculated
for 369.1764 C22H23N2OF2, found 369.1778. Anal.: C22H22N2OF2
requires C 71.72%, H 6.02%, N 7.60%. Found: C 71.36%, H 5.97%,
N 7.39%.
Preparation of 2-(4-(Benzylamino)phenyl)-5,7-diﬂuoro-3-methyl-
quinolin-4(1H)-one 17k. White solid (51%); mp 282−283 °C. 1H
NMR (400 MHz, DMSO) δH 11.39 (s, 1H), 7.36 (dt, J = 15.1, 7.4 Hz,
4H), 7.27−7.21 (m, 3H), 7.13 (d, J = 9.0 Hz, 1H), 6.97 (ddd, J = 12.0,
9.8, 2.3 Hz, 1H), 6.84 (t, J = 6.1 Hz, 1H), 6.72 (d, J = 8.6 Hz, 2H), 4.36
(d, J = 6.1 Hz, 2H), 1.86 (s, 3H). 13C NMR (101 MHz, DMSO) δC
175.36, 164.04, 161.44, 150.01, 148.03, 142.58, 141.46, 140.25, 130.20,
128.73, 127.47, 127.09, 121.61, 116.08, 112.05, 99.34, 98.71, 46.39,
12.56. ES HRMS: m/z found 377.1465, C23H19N2OF2 requires
377.1465. Anal.: C23H18N2OF2 requires C 73.39%, H 4.82%, N
7.44%. Found: C 73.18%, H 4.74%, N 7.41%.
Preparation of 2-(4-(Dimethylamino)phenyl)-5,7-diﬂuoro-3-
methylquinolin-4(1H)-one 17l. White solid (46%); mp 294 °C. 1H
NMR (400 MHz, DMSO) δH 11.48 (s, 1H), 7.37 (d, J = 8.8 Hz, 2H),
7.17 (d, J = 10.1 Hz, 1H), 6.99 (ddd, J = 12.1, 9.6, 2.4 Hz, 1H), 6.86
(d, J = 8.9 Hz, 2H), 2.99 (s, 6H), 1.88 (s, 3H). 13C NMR (101 MHz,
DMSO) δC 175.39, 164.08, 160.75, 151.31, 147.89, 142.77, 130.17,
121.70, 116.20, 111.89, 110.45, 99.38, 98.77, 40.24, 12.55. ESHRMS:m/z
found 315.1319, C18H17N2OF2 requires 315.1309. Anal.: C18H16N2OF2
requires C 68.78%, H 5.13%, N 8.91%. Found: C 68.47%, H 5.14%,
N 8.78%.
Preparation of 2-(4-(4-Benzylpiperidin-1-yl)phenyl)-3-methylqui-
nolin-4(1H)-one 21a.White powder (yield 33%); mp 256−258 °C. 1H
NMR (400MHz, DMSO) δH 11.39 (s, 1H, NH), 8.10 (d, 1H, J = 7.7Hz,
Ar), 7.63−7.55 (m, 2H, AR), 7.37 (d, 2H, J = 8.9 Hz, Ar), 7.33−7.24 (m,
3H, Ar), 7.22−7.17 (m, 3H, Ar), 706 (d, 2H, J = 8.9Hz, Ar), 3.82 (d, 2H,
J = 12.8 Hz, CH2), 2.79−2.66 (m, 2H, CH2), 2.56 (d, 2H, J = 7.0 Hz,
CH2Ar), 1.96 (s, 3H, CH3), 1.79−1.73 (m, 1H, CH), 1.67 (d, 2H, J =
12.9 Hz, CH2), 1.29 (qd, 2H, J = 12.6 Hz, 3.9 Hz, CH2).
13C NMR
(100 MHz, DMSO) δC 177.0, 151.9, 148.3, 140.5, 139.9, 131.3, 130.2,
129.4, 128.5, 126.2, 125.3, 124.5, 123.3, 122.7, 118.4, 115.0, 114.4, 48.7,
42.6, 37.7, 31.5, 12.8. MS (ES+), [M + H]+ (100), 409.2. HRMS
calculated for 409.2280 C28H29N2O, found 409.2289. Anal.: C28H28N2O
requires C 82.32%, H 6.91%, N 6.86%. Found: C 81.98%, H 6.92%,
N 6.88%.
Preparation of 2-(4-(4-Benzylpiperidin-1-yl)phenyl)-6-ﬂuoro-3-
methylquinolin-4(1H)-one 21b. White powder (yield 40%); mp
302−302 °C. 1H NMR (400 MHz, DMSO) δH 11.55 (s,1H, NH),
7.73 (dd, 1H, J = 9.5 Hz, 3.0 Hz, Ar), 7.68 (dd, 1H, J = 9.1 Hz, 4.7 Hz,
Ar), 7.54−7.48 (m, 1H, Ar), 7.38 (d, 2H, J = 8.9 Hz, Ar), 7.33−7.27 (m,
2H, Ar), 7.23−7.17 (m, 3H, Ar), 7.06 (d, 2H, J = 8.9 Hz, Ar), 3.83 (d,
2H, J = 12.7 Hz, CH2), 2.79−2.67 (m, 2H, CH2), 2.55 (d, 2H, J = 7.0 Hz,
CH2Ar), 1.94 (s, 3H, CH3), 1.80−1.68 (m, 1H, CH), 1.67 (d, 2H, J =
13.1 Hz, CH2), 1.28 (qd, 2H, J = 12.6 Hz, 3.9 Hz, CH2).
13C NMR
(100 MHz, DMSO) δC 176.2, 157.1, 152.0, 148.6, 140.5, 136.6, 130.2,
129.4, 128.5, 126.2, 124.3, 121.2, 120.4, 115.0, 113.9, 109.1, 48.4, 42.6,
37.7, 31.4, 12.7. MS (ES+), [M+H]+ (100), 427.2. HRMS calculated for
427.2186 C28H28N2O4F, found 427.2177. Anal.: C28H27N2OF requires
C 78.85%, H 6.38%, N 6.57%. Found: C 78.31%, H 6.35%, N 6.63%.
Preparation of 2-(4-(4-Benzylpiperidin-1-yl)phenyl)-7-methoxy-3-
methylquinolin-4(1H)-one 21c. Light-yellow powder (yield 42%); mp
218−220 °C. 1H NMR (400 MHz, DMSO) δH 11.21 (s, s, 1H, NH),
7.99 (d, 1H, J = 8.9 Hz, Ar), 7.36 (d, 2H, J = 8.7 Hz, Ar), 7.29 (d, 2H, J =
7.2 Hz, Ar), 7.20 (d, 3H, J = 6.4 Hz, Ar), 7.05 (d, 3H, J = 8.6Hz, Ar), 6.87
(dd, 1H, J = 8.9 Hz, 2.4 Hz, Ar), 3.82 (s, 3H, OCH3), 2.71 (t, 2H, J =
11.5 Hz, CH2), 2.56 (d, 2H, J = 6.9 Hz, CH2Ar), 1.91 (s, 3H, CH3),
1.79−1.71 (m, 1H, CH), 1.29 (dt, 2H, J = 11.7 Hz, 8.9 Hz, CH2). 13C
NMR (100 MHz, DMSO) δC 176.7, 161.8, 151.8, 147.8,141.6, 140.5,
130.2, 129.4, 128.5, 127.1, 126.2, 124.6, 117.9, 115.0, 113.9, 113.0, 99.2,
55.6, 48.5, 42.6, 37.7, 31.5, 12.7. MS (ES+), [M + H]+ (100), 439.2.
HRMS calculated for 439.2386 C29H31N2O2, found 439.2386. Purity
HPLC 95% (method B) Rt = 2.43 min.
Preparation of 2-(4-(4-Benzylpiperazin-1-yl)phenyl)-3-methylqui-
nolin-4(1H)-one 21d.White powder (yield 30%); mp 258−260 °C. 1H
NMR (400MHz, DMSO) δH 11.40 (s, 1H, NH), 8.10 (d, 1H, J = 7.7Hz,
AR), 7.63−7.55 (m, 2H, Ar), 7.40 (d, 2H, J = 8.9 Hz, Ar), 7.37−7.33 (m,
3H, Ar), 7.27 (ddd, 2H, J = 10.3 Hz, 5.5 Hz, 2.5 Hz, Ar), 7.08 (d, 2H, J =
8.9 Hz, Ar), 3.54 (s, 2H, CH2Ar), 3.29−3.23 (m, 4H, NCH2), 2.58−2.52
(m, 4H, CH2N), 1.93 (s, 3H, CH3).
13C NMR (100 MHz, DMSO) δC
177.0, 151.9, 148.2, 139.9, 138.4, 131.4, 130.2, 129.3, 128.6, 127.4, 125.3,
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123.3, 122.8, 118.4, 114.9, 114.4, 62.4, 52.8, 49.0, 48.1, 12.7. MS (ES+),
[M + H]+ (100), 410.2. HRMS calculated for 410.2232 C27H28N3O,
found 410.2234. Anal.: C27H27N3O requires C 79.19%, H 6.65%, N
10.26%. Found: C 78.63%, H 6.66%, N 10.21%.
Preparation of 2-(4-(4-Benzylpiperazin-1-yl)phenyl)-6-ﬂuoro-3-
methylquinolin-4(1H)-one 21e. White powder (yield 28%); mp
306−308 °C. 1H NMR (400 MHz, DMSO) δH 11.69 (s, 1H, NH),
7.74−7.71 (m, 2H, Ar), 7.54−7.48 (m, 1H, Ar), 7.40 (d, 2H, J = 8.9 Hz,
Ar), 7.37−7.33 (m, 4H, Ar), 7.08 (d, 2H, J = 8.9 Hz, Ar), 3.54 (s, 2H,
CH2Ar), 3.30−3.22 (m, 4H, CH2N), 2.59−2.52 (m, 4H, NCH2), 1.94
(s, 3H, CH3).
13C NMR (100 MHz, DMSO) δC 151.9, 148.6, 138.4,
136.7, 130.2, 129.3, 128.6, 127.4, 124.9, 124.2, 120.4, 114.8, 113.9, 109.0,
62.4, 55.3, 52.8, 48.0, 12.8. MS (ES+), [M + H] + (100), 428.2. HRMS
calculated for 428.2138 C27H27N3OF, found 428.2138. Purity HPLC
98% (method A) Rt = 1.82 min..
Preparation of 7-Methoxy-3-methyl-2-(4-(4-phenylpiperazin-1-
yl)phenyl)quinolin-4(1H)-one 21f. White powder (yield 30%); mp
312−314 °C. 1H NMR (400 MHz, DMSO) δH 11.25 (s, 1H, NH), 8.01
(d, 1H, J = 9.0 Hz, Ar), 7.43 (d, 2H, J = 8.8 Hz, Ar), 7.26 (dd, 2H, J =
8.4Hz, Ar), 7.16 (d, 2H, J = 8.8 Hz, Ar), 7.05 (d, 1H, J = 2.4 Hz, Ar), 7.02
(d, 2H. J = 8.0 Hz, Ar), 6.88 (dd, 1H, J = 9.0 Hz, Ar), 6.83 (t, 1H, J =
7.3 Hz, Ar), 3.82 (s, 3H, OCH3), 3.41 (dd, 4H, J = 6.5 Hz, 3.5 Hz,
NCH2), 3.31 (dd, 4H, J = 6.5 Hz, 3.5 Hz, CH2N), 1.92 (s, 3H, CH3).
13C
NMR (100 MHz, DMSO) δC 176.7, 161.8, 151.7, 151.3, 147.7, 141.6,
130.2, 129.4, 127.1, 125.6, 119.6, 117.9, 116.1, 115.1, 114.0, 113.0,
99.2, 55.7, 48.6, 48.1, 12.6. MS (ES+), [M + H] + (100), 426.2. HRMS
calculated for 426.2182 C27H28N3O2, found 426.2184. Purity HPLC
91% (method A) Rt = 1.80 min.
Preparation of 2-(4-(4-Benzylpiperazin-1-yl)phenyl)-7-methoxy-
3-methylquinolin-4(1H)-one 21g. White powder (yield 38%); mp
280−282 °C. 1H NMR (400 MHz, DMSO) δH 11.22 (s, 1H, NH), 8.00
(d, 1H, J = 9.0 Hz, AR), 7.38 (d, 2H, J = 8.9 Hz, Ar), 7.37−7.33 (m, 4H,
Ar), 7.31−7.24 (m, 1H, Ar), 7.07 (d, 2H, J = 8.9 Hz, Ar), 7.04 (d, 1H, J =
2.4 Hz, Ar), 6.87 (dd, 1H, J = 8.9 Hz, 2.4 Hz, Ar), 3.82 (s, 3H, OCH3),
3.54 (s, 2H, NCH2Ar), 3.29−3.23 (m, 4H, NCH2), 2.57−2.52 (m, 4H,
CH2N), 1.91 (s, 3H, CH3).
13C NMR (100 MHz, DMSO) δC 176.7,
161.8, 151.8, 147.7, 141.6, 138.4, 130.1, 129.3, 128.6, 127.4, 125.3, 117.9,
114.8, 113.0, 99.2, 62.4, 55.6, 52.8, 49.0, 48.0, 12.6. MS (ES+), [M+H] +
(100), 440.2. HRMS calculated for 440.2338 C28H30N3O2, found
440.2344. Anal.: C28H29N3O2 requires C 76.51%, H 6.65%, N 9.56%.
Found: C 76.12%, H 6.63%, N 9.48%.
Preparation of 5,7-Diﬂuoro-3-methyl-2-(3-(piperidin-1-yl)-
phenyl)quinolin-4(1H)-one 24. White solid (yield 45%); mp 269−
270 °C. 1HNMR (400MHz, DMSO) δH 11.63 (s, 1H, NH), 7.37 (t, J =
7.9 Hz, 1H, Ar), 7.16 (d, J = 9.8 Hz, 1H, Ar), 7.10 (dd, J = 8.4, 2.3 Hz,
1H, Ar), 7.06−6.97 (m, 2H, Ar), 6.86 (d, J = 7.5 Hz, 1H, Ar), 3.27−3.19
(m, 4H, CH2), 1.83 (s, 3H, CH3), 1.62 (d, J = 4.0 Hz, 4H, CH2), 1.59−
1.50 (m, 2H, CH2).
13C NMR (101 MHz, DMSO) δC 175.48, 163.86
(dd, J = 65.8, 15.2 Hz), 161.33 (dd, J = 80.6, 14.7 Hz), 151.93, 148.14,
142.72 (dd, J = 14.7, 6.4 Hz), 135.62, 129.68, 118.86, 116.90, 116.66,
116.07, 110.74 (d, J = 10.7 Hz), 99.66 (dd, J = 24.4, 4.5 Hz), 99.06
(dd, J = 26.8, 25.8 Hz), 49.65, 25.57, 24.33, 12.44. HRMS (ESI)
C21H20N2OF2
23Na [M+H]+ requires 377.1441, found 377.1448 (100%).
Anal.: C21H20N2OF2 requires C 71.17%, H 5.69%, N 7.90%. Found:
C 70.78%, H 5.59%, N 7.64%.
Preparation of 1-(4-(5,7-Diﬂuoro-3-methyl-4-oxo-1,4-dihydroqui-
nolin-2-yl)phenyl)-1H-pyrrole-2-carbonitrile 32a. White solid (55%);
mp 312 °C. 1H NMR (400 MHz, DMSO) δH 11.81 (s, 1H), 7.84−7.74
(m, 4H), 7.67 (dd, J = 2.8, 1.6 Hz, 1H), 7.31 (dd, J = 4.0, 1.6 Hz, 1H),
7.15 (d, J = 10.0 Hz, 1H), 7.06 (ddd, J = 12.0, 9.6, 2.4 Hz, 1H), 6.52
(dd, J = 3.9, 2.8 Hz, 1H), 1.86 (s, 3H). 13C NMR (101MHz, DMSO) δC
175.33, 161.19, 146.24, 142.77, 138.87, 134.57, 130.86, 128.96, 128.22,
124.59, 123.61, 117.07, 114.20, 111.64, 110.81, 103.09, 99.47, 99.21,
12.25. HRMS (ESI) C21H14N3OF2 [M + H]
+ requires 362.1099, found
362.1108 (100%). Anal.: C21H13N3OF2 requires C 69.80%, H 3.63%, N
11.63%. Found: C 69.67%, H 3.66%, N 11.38%.
Preparation of 2-(4-(1H-indol-1-yl)phenyl)-5,7-diﬂuoro-3-methyl-
quinolin-4(1H)-one 32b. White solid (57%); mp decomposed at
325 °C. 1HNMR(400MHz,DMSO) δH 11.79 (s, 1H), 7.84 (d, J = 8.5Hz,
2H), 7.81−7.74 (m, 3H), 7.69 (t, J = 8.6 Hz, 2H), 7.26 (t, J = 7.7 Hz, 1H),
7.22−7.14 (m, 2H), 7.06 (ddd, J = 12.0, 9.7, 2.4 Hz, 1H), 6.78 (d, J =
3.3 Hz, 1H), 1.91 (s, 3H); 13C NMR (101 MHz, DMSO) δC 175.38,
146.64, 142.71, 140.41, 137.96, 135.25, 132.43, 130.93, 129.74, 128.77,
123.87, 122.96, 121.51, 120.98, 117.40, 117.01, 110.75, 104.64, 99.47,
99.13, 96.43, 12.35. HRMS (ESI) C24H17N2OF2 [M + H]
+ requires
387.1303, found 387.1300 (100%). Anal.: C24H16N2OF2 requires C
74.60%, H 4.17%, N 7.25%. Found: C 74.21%, H 4.17%, N 7.24%.
Preparation of 2-(4-(1H-Pyrazol-1-yl)phenyl)-5,7-diﬂuoro-3-
methylquinolin-4(1H)-one 32c. White solid (yield 35%); mp 306 °C.
1H NMR (400MHz, DMSO) δH 11.73 (s, 1H, NH), 8.66 (d, J = 2.5 Hz,
1H), 8.07 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 1.6 Hz, 1H), 7.70 (d, J =
8.5 Hz, 2H), 7.16 (d, J = 9.8 Hz, 1H), 7.05 (ddd, J = 11.9, 9.7, 2.3 Hz,
1H), 6.74−6.53 (m, 1H), 1.87 (s, 3H, CH3). 13C NMR (101 MHz,
DMSO) δC 175.47 (CO), 163.94 (dd, J = 72.7, 14.9 Hz, C−F),
161.40 (dd, J = 87.4, 15.3 Hz, C−F), 146.70, 142.81 (dd, J = 14.6, 6.2
Hz), 142.04, 140.83, 132.36, 130.81, 128.55, 118.62, 117.04, 110.80
(d, J = 8.8 Hz), 108.85, 99.70 (dd, J = 24.4, 4.5 Hz), 99.09 (d, J =
25.2 Hz), 12.40 (CH3). HRMS (ESI) C19H13N3OF2
23Na [M + Na]+
requires 360.0924, found 360.0935. Anal.: C19H13N3OF2 requires C
67.65%, H 3.88%, N 12.46%. Found: C 67.26%, H 4.00%, N 12.24%.
Preparation of 2-(4-(1H-Pyrrol-1-yl)phenyl)-5-ﬂuoro-3-methylqui-
nolin-4(1H)-one 32d.White solid (yield 32%); mp >300 °C. 1H NMR
(400 MHz, DMSO) δH 11.66 (s, 1H, NH), 7.96−7.73 (m, 2H), 7.67−
7.61 (m, 2H), 7.61−7.49 (m, 3H), 7.42 (d, J = 8.4 Hz, 1H), 6.97 (dd, J =
12.1, 7.9 Hz, 1H), 6.49−6.14 (m, 2H), 1.88 (s, 3H, CH3). 13C NMR
(101MHz, DMSO) δC 175.85 (CO), 162.15, 159.57, 146.57, 142.23,
142.21 (d, J = 4.4 Hz), 140.89, 132.06 (d, J = 10.8 Hz), 131.60, 130.84,
119.35 (d, J = 12.6 Hz), 116.59, 114.53, 113.36 (d, J = 8.8 Hz), 111.37,
108.68 (d, J = 20.9 Hz), 12.46 (CH3). HRMS (ESI) C20H15N2OF
23Na
[M + Na]+ requires 341.1066, found 341.1080. Anal.: C20H15N2OF
requires C 75.46%, H 4.75%, N 8.80%. Found: C 75.23%, H 4.70%,
N 8.72%.
Preparation of 2-(4-(1H-pyrrol-1-yl)phenyl)-5,7-diﬂuoro-3-meth-
ylquinolin-4(1H)-one 32e. White solid (41 mg, 30%). 1H NMR (400
MHz, DMSO) δH 11.65 (s, 1H, NH), 7.96 − 7.73 (m, 2H), 7.69 − 7.63
(m, 2H), 7.61− 7.45 (m, 2H), 7.42 (d, J = 8.3 Hz, 1H), 6.95 (dd, J = 12.1,
8.0 Hz, 1H), 6.49 − 6.15 (m, 2H), 1.87 (s, 3H, CH3); 13C NMR
(101 MHz, DMSO) δC 175.85 (C=O), 162.05, 158.57, 146.37, 142.24,
142.25, 140.91, 135.01, 131.62, 130.57, 118.38, 117.61, 114.58, 112.56,
111.38, 108.12, 12.51.HRMS (ESI)C20H14N2 F2O
23Na [M+Na]+ requires
359.0972, found 359.0969. Purity HPLC 98% (method A) Rt = 2.29 min.
Preparation of 2-(3-Chloro-4-(1H-pyrrol-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 32f. White solid (yield 39%);
mp 297−298 °C. 1H NMR (400 MHz, DMSO) δH 11.79 (s, 1H, NH),
7.92 (s, 1H), 7.75−7.57 (m, 2H), 7.19−7.01 (m, 4H), 6.32 (t, J = 2.1 Hz,
2H), 1.87 (s, 3H, CH3).
13C NMR (101 MHz, DMSO) δC 175.42,
164.30, 161.92 (d, J = 14.8 Hz), 160.97 (d, J = 15.3 Hz), 145.27, 142.84,
139.25, 134.90, 131.52, 129.60, 128.42, 128.35, 122.63, 117.30, 110.23,
99.72 (d, J = 19.1 Hz), 99.24 (d, J = 26.0 Hz), 12.30. HRMS (ESI)
C20H13N2OF2
35Cl23Na [M + Na]+ requires 393.0582, found 393.0592.
Anal.: C20H13N2OF requires C 64.79%, H 3.53%, N 7.56%. Found:
C 64.66%, H3.69%, N 7.39%.
Preparation of 5,7-Diﬂuoro-2-(2-ﬂuoro-4-(1H-pyrrol-1-yl)phenyl)-
3-methylquinolin-4(1H)-one 32g.White solid (yield 39%); mp 307 °C.
1H NMR (400 MHz, DMSO) δH 11.82 (s, 1H, NH), 7.84 (dd, J = 11.8,
1.9 Hz, 1H), 7.77−7.64 (m, 2H), 7.62−7.55 (m, 2H), 7.18−6.99
(m, 2H), 6.40−6.23 (m, 2H), 1.79 (s, 3H, CH3). HRMS (ESI)
C20H14N2OF3 [M + H]
+ requires 355.1058, found 355.1074. Anal.:
C20H13N2OF3 requires C 67.79%, H 3.70%, N 7.91%. Found: C 66.94%,
H 3.68%, N 7.73%.
Preparation of (R)-5,7-Diﬂuoro-2-(4-(3-ﬂuoropyrrolidin-1-yl)-
phenyl)-3-methylquinolin-4(1H)-one 38a. White solid (45%); mp
313−314 °C. 1H NMR (400 MHz, DMSO) δH 11.47 (s, 1H), 7.38
(d, J = 8.7 Hz, 2H), 7.18 (d, J = 9.3 Hz, 1H), 6.99 (ddd, J = 12.0, 9.6,
2.4 Hz, 1H), 6.73 (d, J = 8.7 Hz, 2H), 5.50 (d, J = 54.1 Hz, 1H), 3.71−
3.36 (m, 4H), 2.38−2.12 (m, 2H), 1.89 (s, 3H), 13C NMR (101 MHz,
DMSO) δC 175.38, 148.31, 147.92, 142.70, 130.35, 121.60, 116.19,
111.70, 110.56, 99.39, 98.76, 94.49, 92.78, 54.48, 45.59, 32.14,
31.93, 12.58. ES HRMS: m/z found 359.1385, C20H18N2OF3 requires
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359.1371. Anal.: C20H17N2OF3 requires C 67.03%, H 4.78%, N 7.82%.
Found: C 67.26%, H 4.73%, N 7.81%.
Preparation of (S)-5,7-Diﬂuoro-2-(4-(3-ﬂuoropyrrolidin-1-yl)-
phenyl)-3-methylquinolin-4(1H)-one 38b. White solid (47%); mp
313−314 °C. 1H NMR (400 MHz, DMSO) δH 11.47 (s, 1H), 7.38
(d, J = 8.6 Hz, 2H), 7.18 (d, J = 9.2 Hz, 1H), 6.99 (ddd, J = 12.0, 9.7,
2.4 Hz, 1H), 6.73 (d, J = 8.7 Hz, 2H), 5.50 (d, J = 54.3 Hz, 1H), 3.69−
3.36 (m, 4H), 2.36−2.13 (m, 2H), 1.89 (s, 3H). 13C NMR (101 MHz,
DMSO) δC 175.38, 148.32, 147.93, 142.78, 130.36, 121.60, 116.19,
111.70, 110.54, 99.36, 98.76, 94.49, 92.78, 54.48, 45.59, 32.14,
31.93, 12.58. ES HRMS: m/z found 359.1381, C20H18N2OF3 requires
359.1371. Anal.: C20H17N2OF3 requires C 67.03%, H 4.78%, N 7.82%.
Found: C 67.25%, H 4.67%, N 7.86%.
Preparation of 2-(4-(3,3-Diﬂuoroazetidin-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 38c. White solid (33%); mp
316−318 °C. 1H NMR:(400 MHz, DMSO) δH 11.54 (s, 1H), 7.43
(d, J = 8.4 Hz, 2H), 7.16 (d, J = 9.6 Hz, 1H), 7.01 (t, J = 10.8 Hz, 1H),
6.74 (d, J = 8.5 Hz, 2H), 4.37 (t, J = 12.3 Hz, 4H), 1.86 (s, 3H). 13C
(101 MHz, DMSO) δC 175.39, 150.88, 147.53, 142.81, 130.18, 124.67,
117.01, 116.50, 112.70, 110.53, 99.41, 98.90, 90.56, 74.81, 63.29, 12.44.
ES HRMS: m/z found 363.1130, C19H15N2OF4 requires 363.1121.
Anal.: C19H14N2OF4 requires C 62.98%, H 3.89%, N 7.73%. Found:
C 63.03%, H 3.79%, N 7.71%.
Preparation of 2-(4-(3,4-Diﬂuoro-1H-pyrrol-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 38d. White solid (38 mg, 30%).
1H NMR (400 MHz, DMSO) δH 11.78 (bs, 1H), 7.83 (d, J = 8.8 Hz,
2H), 7.72 (d, J = 8.8 Hz, 4H), 7.14 (d, J = 9.6 Hz, 1H), 7.11 (dd, J = 11.0,
10.6 Hz, 1H), 1.91 (s, 3H). 13C NMR (100 MHz, DMSO) δC 175.1,
146.8, 140.3, 131.8, 130.8, 118.7, 116.9, 103.0, 12.3. MS (ES+) m/z 373
(M + H)+. HRMS calculated for 373.0964 C20H13N2OF4, found
373.0965. Purity HPLC 98% (method A) Rt = 2.60 min.
Preparation of 2-(4-(3,4-Diﬂuoro-1H-pyrrol-1-yl)phenyl)-7-me-
thoxy-3-methylquinolin-4(1H)-one 38e. White solid (0.12 g, 32%).
1H NMR (400 MHz, DMSO) δH 11.48 (bs, 1H), 8.02 (d, J = 9.2 Hz,
1H), 7.75 (d, J = 8.8 Hz, 2H), 7.66 (m, 4H), 7.01 (s, 1H), 6.90 (d, J =
9.0 Hz, 1H), 3.82 (s, 3H), 1.90 (s, 3H). 13C NMR (100 MHz, DMSO)
δC 176.5, 161.9, 141.8, 141.1, 140.0, 138.9, 138.7, 130.8, 127.2, 118.6,
118.0, 114.3, 113.3, 102.7, 102.5, 102.4, 99.2,. 55.7, 12.5. MS (ES+) m/z
367 (M + H)+. HRMS calculated for 367.1258 C21H17N2O2F2, found
367.1257. Purity HPLC 99+% (method A) Rt = 2.09 min.
Preparation of 6-Chloro-2-(4-(3,4-diﬂuoro-1H-pyrrol-1-yl)-
phenyl)-7-methoxy-3-methylquinolin-4(1H)-one 38f. White solid
(0.11 g, 30%). 1H NMR (400 MHz, DMSO) δH 11.75 (bs, 1H), 8.03
(s, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.63 (m, 4H), 7.15 (s, 1H), 3.89 (s,
3H), 1.91 (s, 3H). 13C NMR (100MHz, DMSO) δC 175.1, 156.3, 139.7,
138.7, 130.8, 126.0, 118.5, 114.2, 102.7, 102.5, 102.4, 56.5, 12.9. MS
(ES+) m/z 401 (M + H)+. HRMS calculated for 401.0868
C21H16N2O2F2
35Cl, found 401.0870. Purity HPLC 97% (method A)
Rt = 2.35 min..
Preparation of 5,7-Diﬂuoro-2-(4-(3-hydroxy-3-methylpiperidin-1-
yl)phenyl)-3-methylquinolin-4(1H)-one 38g. While solid (48%); mp
decomposed at 284 °C. 1H NMR (400 MHz, DMSO) δH 11.47 (s, 1H),
7.35 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 9.2 Hz, 1H), 7.07−6.94 (m, 3H),
4.46 (s, 1H), 3.30−3.02 (m, 4H), 1.88 (s, 3H), 1.86−1.75 (m, 1H),
1.63−1.48 (m, 3H), 1.17 (s, 3H). 13C NMR (101 MHz, DMSO) δC
175.37, 163.50, 161.49, 152.33, 147.68, 142.79, 130.15, 123.19, 116.27,
114.64, 110.56, 99.34, 98.82, 67.64, 59.76, 47.81, 37.73, 27.28,
22.10, 12.52. ES HRMS: m/z found 385.1738, C22H23N2O2F2 requires
385.1728. Anal.: C22H22N2O2F2 requires C 68.74%, H 5.77%, N 7.29%.
Found: C 68.49%, H 5.84%, N 7.39%.
Preparation of 5,7-Diﬂuoro-2-(4-(3-hydroxy-3-methylpyrrolidin-
1-yl)phenyl)-3-methylquinolin-4(1H)-one 38h. White solid (50%);
mp 288−290 °C. 1H NMR (400 MHz, DMSO) δH 11.43 (s, 1H), 7.35
(d, J = 8.7 Hz, 2H), 7.18 (d, J = 10.1 Hz, 1H), 6.98 (ddd, J = 12.0, 9.6, 2.5
Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 4.85 (s, 1H), 3.48−3.36 (m, 2H), 3.24
(s, 2H), 2.01−1.92 (m, 2H), 1.89 (s, 3H), 1.37 (s, 3H). 13C NMR (101
MHz, DMSO) δC 175.38, 160.89, 155.31, 148.73, 148.07, 130.29,
120.65, 116.06, 111.02, 99.38, 96.34, 94.24, 91.71, 75.74, 60.95, 55.28,
46.88, 26.29, 12.63. ESHRMS:m/z found 399.1391, C21H20N2O2F2
23Na
requires 393.1391. Purity HPLC 98% (method A) Rt = 2.25 min.
Preparation of 5,7-Diﬂuoro-2-(4-(3-hydroxy-3-methylazetidin-1-
yl)phenyl)-3-methylquinolin-4(1H)-one 38i. White solid (43%); mp
decomposed at 289 °C. 1H NMR (400 MHz, DMSO) δH 11.48 (s, 1H),
7.35 (d, J = 8.6 Hz, 2H), 7.16 (d, J = 9.1 Hz, 1H), 6.99 (ddd, J = 12.0, 9.6,
2.4 Hz, 1H), 6.58 (d, J = 8.6 Hz, 2H), 5.60 (s, 1H), 3.83 (d, J = 7.9 Hz,
2H), 3.69 (d, J = 7.7 Hz, 2H), 1.86 (s, 3H), 1.48 (s, 3H). 13C NMR
(101 MHz, DMSO) δC 175.38, 160.90, 152.74, 147.89, 142.69, 136.81,
134.24, 130.07, 122.72, 116.28, 111.45, 99.62, 98.81, 67.73, 66.17, 27.02,
12.52. ES HRMS: m/z found 379.1237, C20H18N2O2F2
23Na requires
379.1234. Anal.: C20H18N2O2F2 requires C 67.41%, H 5.09%, N 7.86%.
Found: C 67.18%, H 5.49%, N 7.24%.
Preparation of (S)-2-(4-(2-((Benzyloxy)methyl)pyrrolidin-1-yl)-
phenyl)-5,7-diﬂuoro-3-methylquinolin-4(1H)-one 38j. Cream solid
(0.10 g, 20%). 1HNMR (400MHz, DMSO) δH 10.60 (bs, 1H), 7.33 (m,
6H), 7.22 (d, J = 8.8 Hz, 2H), 6.56 (dd, J = 11.0, 10.6 Hz, 1H), 6.44
(d, J = 8.8 Hz, 2H), 4.52 (s, 2H), 3.84 (m, 1H), 3.51 (dd, J = 8.8, 4.5 Hz,
1H), 3.30 (m, 2H), 3.05 (m, 1H), 2.05 (m, 4H), 1.92 (s, 3H). 13C NMR
(100 MHz, DMSO) δC 177.1, 148.8, 147.9, 138.1, 129.7, 128.4, 127.8,
127.6, 121.5, 117.2, 111.3, 99.2, 73.4, 70.0, 58.2, 48.3, 28.9, 23.2,
12.4. MS (ES+) m/z 461 (M + H)+. HRMS calculated for 461.2041
C28H27N2O2F2, found 461.2055.
General Procedure for the Preparation of Compounds 39a−c.
Preparation of (S)-5,7-Diﬂuoro-2-(4-(2-(hydroxymethyl)pyrrolidin-1-
yl)phenyl)-3-methylquinolin-4(1H)-one 39a. Cream solid (50 mg,
90%). 1H NMR (400 MHz, DMSO) δH 11.45 (bs, 1H), 7.35 (d, J =
8.8 Hz, 2H), 7.20 (dd, J = 8.0, 4.5 Hz, 1H), 7.01 (dd, J = 11.0, 10.6 Hz,
1H), 6.75 (d, J = 8.8 Hz, 2H), 4.90 (m, 1H), 3.81 (m, 1H), 3.75 (m, 1H),
3.50 (m, 1H), 3.22 (m, 1H), 3.10 (m, 1H), 2.03 (m, 4H), 1.92 (s, 3H).
13C NMR (100 MHz, DMSO) δC 175.4, 148.4, 148.0, 130.3, 121.1,
116.1, 111.7, 99.3, 61.3, 60.5, 48.5, 28.3, 23.0, 12.6. MS (ES+) m/z 371
(M + H)+. HRMS calculated for 371.1571 C21H21N2O2F2, found
371.1568. Purity HPLC 96% (method A) Rt = 2.25 min.
Preparation of (R)-5,7-Diﬂuoro-2-(4-(2-(hydroxymethyl)-
pyrrolidin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 39b. Light-yel-
low solid (0.065 g, 85%). 1H NMR (400 MHz, DMSO) δH 11.44 (bs,
1H), 7.35 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 8.0 Hz, 1H), 6.99 (dd, J = 11.0,
10.6 Hz, 1H), 6.75 (d, J = 8.8 Hz, 2H), 4.84 (dd, J = 5.8, 5.8 Hz, 1H),
3.77 (m, 1H), 3.51 (m, 1H), 3.42 (m, 1H), 3.25 (m, 1H), 3.08 (m, 1H),
1.98 (m, 4H), 1.89 (s, 3H). 13C NMR (100 MHz, DMSO) δC 175.7,
148.8, 148.0, 130.3, 121.1, 116.2, 111.7, 99.9, 61.5, 60.5, 28.5, 23.6, 12.6.
MS (ES+) m/z 371 (M + H)+. HRMS calculated for 371.1571
C21H21N2O2F2, found 371.1572. Purity HPLC 97% (method A) Rt =
2.24 min.
Preparation of (R)-2-(4-(3-(Aminomethyl)pyrrolidin-1-yl)phenyl)-
5,7-diﬂuoro-3-methylquinolin-4(1H)-one 39c. White solid (21 mg,
93%). 1H NMR (400 MHz, DMSO) δH 11.48 (bs, 1H), 7.40 (m, 1H),
7.38 (d, J = 8.8 Hz, 2H), 7.21 (d, J = 8.4 Hz, 1H), 6.99 (dd, J = 11.0,
10.6 Hz, 1H), 6.86 (d, J = 8.8 Hz, 2H), 4.09 (m, 1H), 3.20 (m, 1H), 2.99
(m, 1H), 2.51 (d, J = 10.4 Hz, 1H), 2.31 (dd, J = 14.4, 10.9 Hz, 1H), 2.13
(m, 1H), 1.98 (s, 3H), 1.82 (m, 2H), 1.63 (m, 2H). 13C NMR
(100 MHz, DMSO) δC 175.4, 147.8, 130.4, 116.2, 112.0, 111.6, 99.7,
56.5, 56.2, 48.3, 34.6, 28.5, 12.6. MS (ES+) m/z 370 (M + H)+. HRMS
calculated for 370.1731 C21H22N3OF2, found 370.1738. Purity HPLC
96% (method A) Rt = 1.61 min.
Preparation of 2-(4-(3,3-Diﬂuoropyrrolidin-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 42a. White solid (56%); mp
decomposed at 316 °C. 1H NMR (400 MHz, DMSO) δH 7.41 (d, J =
8.7 Hz, 2H), 7.17 (d, J = 9.0 Hz, 1H), 7.01 (ddd, J = 12.0, 9.6, 2.4 Hz,
1H), 6.78 (d, J = 8.8 Hz, 2H), 3.79 (t, J = 13.3 Hz, 1H), 3.56 (t, J =
7.2 Hz, 1H), 2.59 (tt, J = 14.5, 7.3 Hz, 1H), 1.87 (s, 1H). 13C NMR
(101 MHz, DMSO) δ 175.38, 164.09, 148.09, 147.72, 142.82, 130.34,
129.16, 126.71, 122.79, 116.32, 111.98, 111.61, 99.37, 98.82, 54.96,
45.75, 33.72, 12.54. ESHRMS:m/z found 399.1093, C20H16N2OF4
23Na
requires 399.1096. Anal.: C20H16N2OF4 requires C 63.83%, H 4.29%,
N 7.44%. Found: C 63.49%, H 4.31%, N 7.28%.
Preparation of 2-(4-(3,3-Diﬂuoropiperidin-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4(1H)-one 42b. White solid (47%); mp
decomposed at 297 °C. 1H NMR (400 MHz, DMSO) δH 11.54
(s, 1H), 7.39 (d, J = 8.8 Hz, 2H), 7.20−7.11 (m, 3H), 7.01 (ddd, J = 12.0,
9.6, 2.4 Hz, 1H), 3.65 (t, J = 11.9 Hz, 2H), 3.43−3.37 (m, 2H), 2.16−
2.01 (m, 2H), 1.87 (s, 3H), 1.85−1.75 (m, 2H). 13C NMR (101 MHz,
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DMSO) δC 175.38, 152.75, 150.88, 147.47, 142.69, 130.26, 124.51,
121.44, 116.43, 115.09, 113.88, 110.51, 99.67, 98.87, 53.21, 52.92, 46.93,
32.09, 21.59, 12.47. ES HRMS: m/z found 391.1441, C21H19N2OF4
requires 391.1434. Anal.: C21H18N2OF4 requires C 64.61%, H 4.65%,
N 7.18%. Found: C 64.06%, H 4.61%, N 7.05%.
Preparation of (R)-N-(tert-Butyl)-1-(4-(3-methyl-4-oxo-1,4-dihy-
droquinolin-2-yl)phenyl)pyrrolidine-2-carboxamide 45a. Pale-yellow
powder (yield 20%); mp 164−166 °C. 1H NMR (400 MHz, CDCl3-d6)
δH 11.11 (s, 1H,NH), 7.43 (d, 2H, J = 8.6 Hz, Ar), 7.34 (d, 1H, J =
9.6 Hz, Ar), 6.71−6.61 (m, 1H, Ar), 6.55 (d, 2H, J = 8.6 Hz, Ar), 6.28 (s,
1H, NH), 3.59 (t, 1H, J = 7.2 Hz, CH), 2.99 (dd, 1H, J = 15.4 Hz, 8.9 Hz,
CH2), 2.89 (d, 1H, J = 8.6 Hz, CH2), 2.03 (s, 3H, CH3), 1.92−1.65 (m,
4H, CH2), 1.34 (m, 9H, CH3).
13C NMR (100 MHz, CDCl3-d6) δc
173.1, 148.0, 130.1, 125.3, 117.7, 113.1, 64.6, 51.3, 49.8, 31.4, 28.6, 24.0,
12.3. MS (ES+), [M +Na]+ (100) 462.2. HRMS calculated for 462.1969
C25H27O2N3F2Na, found 462.1955. Anal.: C25H27N3O2F2 requires C
68.32%, H 6.19%, N 9.56%. Found: C 68.13%, H 6.10%, N 9.11%.
Preparation of (R)-1-(4-(5,7-Diﬂuoro-3-methyl-4-oxo-1,4-dihy-
droquinolin-2-yl)phenyl)-N,N-dimethylpyrrolidine-2-carboxamide
45b. Pale-yellow powder (yield 34%); mp 176−178 °C. 1H NMR (400
MHz, CDCl3-d6) δH 10.40 (s, 1H, NH), 7.24−7.22 (m, 1H, Ar), 7.12
(d, 2H, J = 8.6 Hz, Ar), 6.73−6.56 (m, 1H, Ar), 6.13 (d, 2H, J = 8.6 Hz,
Ar), 4.22 (dd, 1H.J = 8.8 Hz, 2.1 Hz, CH), 3.46−3.39 (m, 1H, CH2),
3.25 (dd, 1H, J = 16.0 Hz, 8.4 Hz, CH2), 3.16 (s, 3H, NCH3), 2.85 (s,
3H, NCH3), 2.35−2.23 (m, 1H, CH2), 2.20−1.95 (m, 3H, CH2), 1.90
(s, 3H, CH3).
13C NMR (100 MHz, CDCl3-d6) δC 177.7, 172.7, 147.9,
129.6, 122.1, 117.1, 111.0, 58.6, 48.5, 36.9, 36.0, 30.5, 23.6, 15.3, 12.5.
MS (ES+), [M + Na] + (100) 434.2. HRMS calculated for 434.1656
C23H23O2N3F2Na, found 434.1669. Purity HPLC 97% (method B)
Rt = 1.95 min.
Preparation of (R)-1-(4-(5,7-Diﬂuoro-3-methyl-4-oxo-1,4-dihy-
droquinolin-2-yl)phenyl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolidine-
2-carboxamide 45c. Pale-yellow powder (yield 25%); mp 228−230 °C.
1H NMR (400 MHz, CDCl3-d6) δH 10.82 (s, 1H, NH), 7.36 (d, 2H, J =
8.7 Hz, Ar), 7.25 (d, 1H, J = 9.6 Hz, Ar), 6.68−6.59 (m, 1H, Ar), 6.56
(s, 1H, NH), 6.53 (d, 2H, J = 8.7 Hz, Ar), 4.06−3.82 (m, 2H, CH/CH2),
3.66−3.56 (m, 1H, CH2), 3.52−3.39 (m, 3H, CH2),3.30 (d, 1H, J =
6.7 Hz, CH2), 3.11−3.02 (m, 1H, CH2), 2.05−1.71 (m, 9H, CH2/CH3),
1.53−1.30 (m, 2H, CH2). 13C NMR (100 MHz, CDCl3-d6) δC 177.1,
173.1, 148.0, 147.2, 130.0, 124.9, 117.6, 112.9, 66.6, 65.9, 64.1, 49.7,
46.0, 32.9, 31.4, 24.1, 15.3, 12.3. MS (ES+), [M + Na] + (100) 490.2.
HRMS calculated for 490.1018 C26H27O3N3F2Na, found 490.1932.
Purity HPLC 93% (method B) Rt = 1.92 min.
Preparation of (R)-5,7-Diﬂuoro-3-methyl-2-(4-(2-(morpholine-4-
carbonyl)pyrrolidin-1-yl)phenyl)quinolin-4(1H)-one 45d. Pale-yellow
powder (yield 18%); mp 236−238 °C. 1H NMR (400 MHz, CDCl3-d6)
δH 10.26 (s, 1H, NH), 7.20 (d, 1H, J = 9.2 Hz, Ar), 7.14 (d, 2H, J = 8.6
Hz, Ar), 6.67−6.59 (m, 1H, Ar), 6.17 (d, 2H, J = 8.6 Hz, Ar), 4.44−4.37
(m, 1H, CH), 3.78 (dd, 1H, CH2), 3.74−3.55 (m, 6H, CH2), 3.46−3.35
(m, 2H, CH2), 3.27 (dd, 1H, J = 16.1 Hz, 8.3 Hz, CH2), 2.36−2.24 (m,
1H, CH2), 2.18−2.04 (m, 2H, CH2), 2.03−1.96 (m, 1H, CH2), 1.90 (s,
3H, CH3).
13C NMR (100 MHz, CDCl3-d6) δC 171.2, 147.7, 147.0,
129.6, 122.2, 117.2, 111.1, 67.0, 66.5, 58.7, 48.5, 45.8, 42.5, 30.8,
23.6, 12.4. MS (ES+), [M + Na] + (100) 476.2. HRMS calculated
for 476.1762 C25H25O3N3F2Na, found 476.1778. Purity HPLC 93%
(method B) Rt = 1.90 min.
Preparation of (R)-5,7-Diﬂuoro-2-(4-(2-(4-ﬂuoropiperidine-1-
carbonyl)pyrrolidin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 45e.
Pale-yellow powder (yield 24%); mp 238−240 °C. 1H NMR
(400 MHz, CDCl3-d6) δH 10.21 (s, 1H, NH), 7.24−7.08 (m, 3H, Ar),
6.63 (t, 1H, Ar), 6.18 (dd, 2H, J = 7.7Hz, 5.0 Hz, Ar), 5.04−4.81 (m, 1H,
CHF), 4.44 (d, 1H, CH), 3.88−5.59 (m, 3H, CH2), 3.58−3.32 (m, 1H,
CH2), 3.31−3.19 (m, 1H, CH2), 2.40−2.24 (m, 1H, CH2), 2.18−1.61
(m, 11H, CH2).
13CNMR (100MHz, CDCl3-d6) δC 171.4, 148.0, 147.7,
129.6, 122.4, 116.9, 111.1, 65.9, 58.8, 48.5, 38.8, 30.9, 23.9, 12.4. MS
(ES+), [M + Na] + (100) 492.2. HRMS calculated for 492.1875
C26H26O2N3F3Na, found 492.1872. Purity HPLC 96% (method A)
Rt = 2.20 min.
Preparation of 4(R)-1-(4-(5,7-Diﬂuoro-3-methyl-4-oxo-1,4-dihy-
droquinolin-2-yl)phenyl)-N,N-dimethylazetidine-2-carboxamide
45f. White solid (0.056 g, 14%). 1H NMR (400 MHz, (CD3)2SO) δH
1.87 (3 H, s, CH3C), 2.30−2.40, 2.60−2.75 (2 H, 2m, CCH2C), 2.88,
2.94 (6 H, 2s, Me2N), 3.72, 3.93 (2 H, 2m, CH2N), 4.92 (1 H,
approximately t, CHN), 6.51 (2 H, d, ArH), 7.00 (1 H, m, ArH), 7.17 (1
H, m, ArH), 7.33 (2 H, d, ArH) and 11.49 (1 H, br s, NH). 13C NMR
(100MHz, (CD3)2SO) δC 12.5, 22.1, 35.4, 35.8, 49.0, 63.2, 111.5, 116.3,
123.0, 129.8, 148.0, 151.9, 170.5 and 175.4; not all the aromatic carbons
were seen; m/z (ES + ve mode) 398 (MH+, 100%). Found: m/z,
398.1667. C22H22N3O2F2 requiresm/z, 398.1680. Anal.: C22H21N3O2F2
requires C 66.49%, H 5.33%, N 10.57%. Found: C 66.15%, H 5.36%,
N 9.88%.
Preparation of (R)-N-(tert-Butyl)-1-(4-(5,7-diﬂuoro-3-methyl-4-
oxo-1,4-dihydroquinolin-2-yl)phenyl)azetidine-2-carboxamide 45g.
Pale-yellow powder (0.033 g, 12%). 1H NMR (400 MHz, CDCl3) δH
1.42 (9 H, s, Me3C), 2.00 (3 H, s, CH3C), 2.20−2.30 (2 H, m,
CCH2C), 3.26 (1 H, m), 3.58 (1 H, m), 3.95 (1 H, m), 6.52 (2 H, d,
ArH), 6.60−6.70 (1 H, m, ArH), 7.19 (1 H, m, ArH), 7.40 (2 H, d, ArH)
and 10.43 (1 H, br s, NH). m/z (CI, methane) 426 (MH+, base peak).
Found: m/z, 426.1988. C24H26F2N3O2 requires m/z, 426.1986.
Anal.: C24H25N3O2F2 requires C 67.75%, H 5.92%, N 9.88%. Found:
C 67.26%, H 5.88%, N 9.56%.
Preparation of 2-(4-(3,3-Diﬂuoropyrrolidin-1-yl)phenyl)-5,7-di-
ﬂuoro-3-methylquinolin-4-yl acetate 46. To a suspension of 2-(4-
(3,3-diﬂuoropyrrolidin-1-yl)phenyl)-5,7-diﬂuoro-3-methylquinolin-
4(1H)-one (280 mg, 0.74 mmol) in THF (15 mL), tBuOK (172 mg,
1.5 mmol) was added. The resulting mixture was kept stirring at room
temperature for 1 h. After that, excess acetyl chloride (0.2 mL) was
added, and the reaction mixture was kept stirring for 3 h at room
temperature. After that, H2O (15 mL) was used to quench the reaction
and Et2O (50 mL) was used to dilute the mixture. Organic layer was
separated from the water layer, and DCM/MeOH (1:1, 20 mL) was
added to the organic layer to dissolve any precipitation. The organic
solution was dried with MgSO4 and concentrated in vacuo to give
the crude product. The crude product we puriﬁed by ﬂash column
chromatograph eluting with 20% EtOAc in hexane to give the title
product a pale-yellow solid (290 mg, 94%). 1H NMR (400 MHz,
CDCl3) δH 7.72−7.53 (m, 3H), 6.99 (dd, J = 15.1, 5.7 Hz, 1H), 6.66
(d, J = 8.6 Hz, 2H), 3.75 (t, J = 13.2 Hz, 2H), 3.61 (t, J = 7.1 Hz, 2H),
2.54 (ddd, J = 21.2, 14.0, 7.3 Hz, 2H), 2.46 (s, 3H), 2.32 (s, 3H). 13C
NMR (101 MHz, CDCl3) δC 168.52, 163.55, 161.69 (dd, J = 249.3,
14.3 Hz), 157.00 (dd, J = 258.3, 14.3 Hz), 150.99 (t, J = 1.8 Hz), 149.05
(dd, J = 14.2, 2.6 Hz), 147.41, 130.57, 128.55, 128.04, 125.58, 121.90,
111.53, 109.74 (dd, J = 20.6, 5.0 Hz), 109.51 (dd, J = 9.3, 1.8 Hz), 103.05
(dd, J = 29.3, 25.9 Hz), 55.33 (t, J = 31.6 Hz), 45.54 (t, J = 3.2 Hz), 34.28
(t, J = 24.0 Hz), 20.71, 13.71. HRMS (ES) C22H18N2O2F3
23Na [M +
Na]+ requires 441.1202, found 441.1212. Anal.: C22H18N2O2F4 requires
C 63.16%, H 4.34%, N 6.70%. Found: C 62.77%, H 4.29%, N 6.53%.
Biology. Drug Susceptibility Assays Using Replicating and
Hypoxic Mtb. For drug susceptibility assays, aerobic cultures of Mtb
H37Rv were cultured as described previously.14 Cultures were grown
until a mid log growth phase was reached (Middlebrook 7H9 broth with
addition of 10% albumin−dextrose−catalase solution (Becton Dick-
inson), 0.2% (vol/vol] )glycerol, and 0.05% (vol/vol) Tween 80).
Hypoxic cultures of Mtb were produced using the same growth media
but the method described by Wayne and Hayes was utilized,58 where
oxygen supply was limited over 6 weeks and cultures were mixed using
8 mm Teﬂon-coated magnetic stirring bars (120 rpm, 37 °C).
The eﬀectiveness of test drugs to prevent Mtb growth was
determined using a microplate AlamarBlue assay (MABA) as described
previously.14 A range of test drug concentrations (10−0.08 μM, 2%
DMSO) were coincubated with replicating Mtb (OD 0.01, 7 days,
37 °C) followed by a MABA. Measurements of well absorbance at
570 and 600 nm were recorded using an Opsys MR plate reader were
determined to calculate IC50 values for the inhibitors. For anaerobic
cultures, coincubations of hypoxic Mtb and test drug were performed as
described for replicating Mtb, however, the plates were sealed within
GasPak EZ pouches containing an indicator to ensure anaerobic
conditions were maintained. The plates were subsequently incubated
anaerobically (7 days, 37 °C) before being moved to an aerobic environ-
ment for a further 7 days. The IC50 values were calculated as described
for aerobic cultures.
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In Vitro Metabolic Stability. Mixed pools of microsomes from
multiple donors were purchased from BD Biosciences, USA (human,
rat, and mouse) (protein content 20 mg/mL). Compounds of interest
were tested at 10, 1, and 0.1 μMwith a ﬁnal concentration of microsomal
protein of 1 mg/mL. The reaction was initiated by the addition of
NADPH (1mM), and samples were incubated for up to 60 min at 37 °C
in a shaking incubator. The reaction was terminated at 0, 10, 30, and
60 min by the addition of ice-cold ACN/MeOH (50:50) spiked with
internal standard. Sample preparation for mass spectrometry involved
the addition of an equivalent amount of water to each sample before
extraction using ethyl acetate (3 × 500 μL). The organic layer was then
dried under nitrogen before reconstitution in MeOH/H2O (50:50).
Cytotoxicity Assay in HEPG2 Using MTT. The cellular toxicity of test
compounds were determined using the MTT assay, with modiﬁcations,
using HEPG2 cells which were either resistant (cultured using glucose-
containing media) or susceptible (cultured using galactose-containing
media) tomitochondrial-toxicity-induced cell death.59,60 Brieﬂy, HepG2
cells cultured in glucose media (high-glucose Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 25 mM glucose and 1 mM
sodium pyruvate, supplemented with 5 mMHEPES, 10% (vol/vol) fetal
bovine serum (FBS), and 100 μg/mL penicillin−streptomycin) or
galactose media (glucose-free DMEM supplemented with 10 mM
galactose, 5 mM HEPES, 10% (vol/vol) FBS, 1 mM sodium pyruvate,
and 100 μg/mL penicillin−streptomycin) were added to 96-well plates
(60 μL, 1 × 104 cells/well) and incubated for 24 h. Log-range
concentrations of each test compound (1−100 μM) were then added
to the plates and a further incubation of 24 h performed. Plates
were subsequently incubated for 2 h in the presence 1 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solu-
tion. Cell lysis solution (50 μL, 50% (vol/vol) dimethylformamide in
distilled water, 20% (wt/vol) sodium dodecyl sulfate) was added to
wells, and plates were wrapped in metallic foil and mixed at 60 rpm for
2 h at room temperature. Well absorbance at 560 nm was determined
using a Varioskan plate reader (ThermoScientiﬁc) and were used to
determine IC50 values using a four-parameter logistic function using
Prism 5 software. All incubations were performed at 37 °C in a CO2
incubator and compounds were solubilized in DMSO (1% (vol/vol)
ﬁnal concentration). The cytotoxic control compounds rotenone
(0.001−1 μM, toxic to mitochondria) and tamoxifen (1−100 μM, no
speciﬁc mitochondrial toxicity) were included as controls, as was a drug-
free control containing 1% (vol/vol) DMSO.
Caco-2 Trans-Epithelial Drug Transport. Caco-2 monolayer
experiments were performed as previously described,61 with mod-
iﬁcations. When conﬂuent, Caco-2 cells were seeded onto polycar-
bonate membrane transwells at a density of 2.6 × 105 cells/cm2
(DMEM, 15% (vol/vol) FCS) and incubated (37 °C, 5% CO2) for
16 h. Following this incubation, media was replaced to remove dead cells
and to prevent the formation of multiple layers of cells settling on the
ﬁlter. Plate media was changed every 48 h and plates used in experiments
21 days from initial seeding. Monolayer integrity was checked using a
MillicellERS instrument (Millipore) to determine the trans-epithelial
electrical resistance (TEER) across the monolayer. A TEER of more
than 400 Ω/cm2 was deemed acceptable.
On the day of the experiment, the TEER was assessed and the media
replaced with warm transport buﬀer (HBSS, 25 mM HEPES, 0.1%
(wt/vol) bovine serum albumin, pH 7) and allowed to equilibrate
(37 °C, 30 min). The transport buﬀer in the chambers was replaced with
transport buﬀer containing either the test compound or the control drug
verapamil (5 μM). Samples (50 μL) were taken from the receiver
compartment at 0, 60, 120, and 180 min and replaced with an equal
volume of transport buﬀer. Samples were analyzed using LC-MS/MS.
Data were used to determine apparent permeability (Papp, 10
−6 cm/s)
for each direction and eﬄux ratio (ratio of basolateral to apical Papp
compared with apical to basolateral Papp). Papp was calculated using the
following equation as described previously:62
= ×
×
P
Q t V
A C
(d /d )
app
0
dQ/dt is the change in drug concentration in the receiver chamber over
time (nM/s), V is the volume in the receiver compartment (mL), A is
the total surface area of the transwell membrane (cm2), C0 is the initial
drug concentration in the donor compartment (nM), and Papp is the
apparent permeability (× 10−6 cm/s).
Plasma Protein Binding Using Equilibrium Dialysis. The extent of
plasma protein binding for each test compounds was determined by
equilibrium dialysis. Test compound was added to human plasma
which was mixed and heated (1 μM, 1% (vol/vol) DMSO, 37 °C).
Regenerated cellulose membranes (5000 Da, Harvard Apparatus) were
soaked in phosphate buﬀer for 5 min and placed within Fast Micro-
Equilibrium Dialyzers (Harvard Apparatus). One milliliter of plasma
containing the test drug was added to the ﬁrst compartment, and 1mL of
phosphate buﬀer (1% (vol/vol) DMSO, 37 °C)was added to the second
compartment. Equilibrium dialysis was undertaken by incubation
(18 h, 37 °C), and samples were removed from each compartment
for LC-MS/MS analysis.
Plasma Stability. Compounds were incubated in rat or human
plasma (1 μM) at 37 °C for up to 3 h. At various time points (0, 10, 30,
60, 120, and 180 min) an aliquot (100 μL) was taken and the reaction
was terminated by the addition of ice-cold ACN/MeOH (300 μL,
50%:50% (vol/vol)) spiked with internal standard. Samples underwent
centrifugation to remove the protein precipitate and were analyzed
directly using LC-MS/MS analysis.
In Vitro CYPP450 Inhibition. CYPP450 VIVID inhibition kits were
purchased from Invitrogen Life Technologies. Brieﬂy, compounds were
tested at a ﬁnal concentration of 10, 1, and 0.1 μM alongside a relevant
positive control for the isoform of interest and a solvent control.
The assay utilized a substrate, speciﬁc to the isoform, which produced a
ﬂuorescent metabolite as it underwent oxidation by the P450 enzyme.
Inhibition of the enzyme led to reduced ﬂuorescent output. The assay
was carried out in kinetics mode, with a reading being taken every
minute for a total of 1 h.
Pharmacokinetic Studies in Rats. Male Wistar rats (180−250 g)
(n = 4) were purchased from Charles River Laboratories, UK, and
allowed to acclimatize for 1 week in controlled conditions (23 ± 3 °C;
relative humidity 50 ± 10%; light−dark cycle 12 h). Animals were
provided with feed pellet and ﬁltered water ad libitum. Each rat received
an oral dose of the relevant compound (10 or 50 mg/kg) in PEG400
(100%) (5 mL/kg) via gavage needle or an IV injection of the relevant
compound (0.5 mg/kg) in 5% PEG400 and 5% solutol in water.
At various time-points, the rats were anaesthetized using isoﬂurane and
a blood sample (<300 μL) was taken from a superﬁcial vein in the tail.
The blood was immediately stored on ice before undergoing centrifu-
gation at 13000 rpm, for 10 min. An aliquot of 100 μL of plasma was
removed and added to ACN/MeOH (300 μL, 50%:50% (vol/vol))
spiked with internal standard. Samples were then analyzed using
LC-MS/MS within 24 h of obtaining the ﬁnal sample.
PK data were modeled using the package Pmetrics63 utilizing a one
compartment gut absorption model. Separate doses were modeled
separately to diﬀerentiate the eﬀect of dose upon the pharmacokinetic
proﬁle of each compound.
LC-MS/MS. Drug concentration analyses were performed on a TSQ
Quantum Access mass spectrometer (Thermo, UK). Chromatographic
separation for all test compounds and control compounds was per-
formed at 30 °C on a Fortis C-18 3 μm column (50 mm × 2.1 mm i.d.,
Fortis technologies, UK). Mobile phases were solution A (100%
acetonitrile) and solution B (100% LC-MS/MS-grade water, 0.05%
formic acid), and ﬂow rate was 0.3 mL/min. Separation was achieved
with a gradient elution beginning with 90% solution D and 10% solution
A, which was maintained for 1 min. Solution A was then gradually
increased to 80% over 1.9 min and maintained for a further 1.4 min.
Solution B was increased to 90% over 0.7 min and maintained for
0.2 min, giving a total run time of 5.2 min. Robustness of analyses were
assessed using standard concentration curves and quality control concen-
trations, where concentration standard deviations were required to be
within 20% for generated results to be accepted.
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